Recombinant polypeptides, including compositions of such recombinant polypeptides, and their uses and methods thereof.
By introducing specific amino acid mutations into the receptor-binding domain and translocation domain of type A1 botulinum toxin, the problem of insufficient research on type A botulinum toxin subtypes has been solved, resulting in a more efficient and safer recombinant peptide suitable for improving, preventing or treating related diseases.
Patent Information
- Application Number
- CN202580028424.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-11-07
- Filing Date
- 2025-04-15
- Publication Date
- 2026-11-17
AI Technical Summary
In the existing technology, there is extensive research on type A1 botulinum toxin, but there is less research on the pharmacological characteristics of other type A botulinum toxin subtypes, especially their properties in terms of potency, intracellular migration and persistence, which are different from type A1 botulinum toxin. There is also a lack of effective recombinant peptides and compositions.
A recombinant polypeptide is provided, comprising a receptor-binding domain and a translocation domain of type A1 botulinum toxin. Its efficacy and safety are improved by introducing mutations at specific amino acid positions, such as amino acid substitutions or modifications at positions N880, W1068, and N1090.
It enhances the potency and safety of recombinant peptides, exhibiting a longer half-life and a higher safety margin, superior to wild-type A1 botulinum toxin.
Smart Images

Figure CN123125327A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a recombinant polypeptide, and more specifically, to a recombinant polypeptide comprising a receptor-binding domain of type A1 botulinum toxin containing at least one amino acid mutation, or a recombinant type A botulinum toxin light chain and a recombinant type A botulinum toxin receptor-binding domain. Background Technology
[0002] Botulinum toxin (BoNT) is a neurotoxic protein produced by Clostridium botulinum and related species. Botulinum toxin blocks the release of acetylcholine, a neurotransmitter secreted from the axonal terminals of the neuromuscular junction.
[0003] Botulinum toxin is synthesized as a 150 kDa double-chain protein, consisting of a 100 kDa heavy chain and a 50 kDa light chain linked by disulfide bonds. The heavy chain is further divided into an N-terminal domain (Hn) that facilitates the translocation of the light chain into the cytosol, and a C-terminal domain (Hc) that recognizes and binds to cell surface receptors on nerve cells. Once inside the cell, the light chain inactivates neurotransmitter release by specifically proteolytically cleaving a portion of the soluble NSF-attachment protein receptor (SNARE). Botulinum toxin is classified into seven serotypes (botulinum toxin type A, B, C, D, E, F, and G), and further subdivided into subtypes based on amino acid sequence mutations. Among them, A1 botulinum toxin has undergone extensive molecular-level research as well as preclinical and clinical studies, and is currently widely used in the pharmaceutical industry. Conversely, for other subtypes of botulinum toxin A, due to the difficulty in isolating purified toxins, there are fewer studies or reports on their pharmacological characteristics. Currently, only the biochemical, cellular, and in vivo properties of some subtypes of botulinum toxin A have been identified. According to reported studies, various in vitro and in vivo studies of subtypes of botulinum toxin A have revealed characteristics that differ from A1 botulinum toxin in terms of potency, intracellular migration, and persistence mechanisms. Recently, the in vitro properties of A7 and A8 botulinum toxins have been reported. Summary of the Invention
[0004] Technical issues One object of the present invention is to provide a recombinant polypeptide and a recombinant botulinum toxin comprising the same, said recombinant polypeptide comprising at least one of a recombinant receptor-binding domain and a recombinant translocation domain of type A1 botulinum toxin.
[0005] One object of the present invention is to provide a composition relating to a recombinant polypeptide and a recombinant botulinum toxin comprising the recombinant polypeptide, said recombinant polypeptide comprising a recombinant receptor-binding domain and a recombinant translocation domain of type A1 botulinum toxin.
[0006] One object of the present invention is to provide a pharmaceutical use for the composition.
[0007] One object of the present invention is to provide a method for improving, preventing or treating a disease or condition, comprising applying the composition to an individual.
[0008] Technical solution A recombinant polypeptide according to an embodiment of the present invention may include a receptor-binding domain of type A1 botulinum toxin. The receptor-binding domain may include an amino acid mutation at at least one position, wherein the mutation is a conserved common amino acid in type A2 and type A6 botulinum toxins, but a different amino acid at the corresponding position in type A1 botulinum toxin.
[0009] The location of the amino acid mutation may include at least one selected from the group consisting of N880, W1068, and N1090.
[0010] The receptor-binding domain may also include an amino acid mutation at at least one position selected from the group consisting of N954, M968, T990, Q991, N1025, N1026, N1052, T1063, H1064, Y1117, T1232, and L1278. In this specification, for example, "may include an amino acid mutation at position N954" means that asparagine, as the 954th amino acid, is replaced, deleted, or modified by another amino acid.
[0011] The receptor-binding domain may further include at least one amino acid mutation selected from the group consisting of N954S, M968I, T990N, Q991K, N1025T, N1026K, N1052K, T1063P, H1064R, Y1117F, T1232R, and L1278F.
[0012] The receptor-binding domain may also include an amino acid mutation at at least one position selected from the group consisting of N954, M968, T990, Q991, N1025, N1026, N1052, T1232, and L1278.
[0013] The receptor-binding domain may include at least one amino acid mutation selected from the group consisting of N954S, M968I, T990N, Q991K, N1025T, N1026K, N1052K, T1232R, and L1278F.
[0014] One embodiment of the recombinant polypeptide further includes a translocation domain, which may comprise a polypeptide selected from the group consisting of translocation domains of botulinum toxin type A1, botulinum toxin type A2, botulinum toxin type A6, and variants thereof. For example, the translocation domain may comprise, or be composed of, the translocation domain of botulinum toxin type A1 or a variant thereof.
[0015] One embodiment of the recombinant polypeptide includes a translocation domain of type A1 botulinum toxin, said translocation domain may include an amino acid mutation at at least one position, said position being a conserved common amino acid in type A2 and type A6 botulinum toxin, but a different amino acid at the corresponding position in type A1 botulinum toxin. Alternatively, one embodiment of the recombinant polypeptide includes a translocation domain of type A1 botulinum toxin and may include a mutation at amino acid position 589.
[0016] One embodiment of the recombinant polypeptide includes a translocation domain of type A1 botulinum toxin, wherein the amino acid mutation position of the translocation domain may include at least one selected from the group consisting of D589, L681, D696, I713, K730, E734, K779, N789, G804, E809, L815, K816, and A818.
[0017] The translocation domain may include at least one amino acid mutation selected from the group consisting of D589K, E734K, and E809K.
[0018] One embodiment of the recombinant polypeptide further includes a light chain domain, which may include a polypeptide selected from the group consisting of botulinum toxin type A1, botulinum toxin type A4, and their variants.
[0019] The light chain domains may include the first and second domains of the A1 type botulinum toxin light chain; or variants thereof, and the third and fourth domains of the A4 type botulinum toxin light chain; or variants thereof.
[0020] The variant light chain may include a first and second domain of the A1 type botulinum toxin light chain and a third and fourth domain of the A4 type botulinum toxin light chain, wherein the leucine at position 260 in the light chain domain is replaced by phenylalanine and the isoleucine at position 264 is replaced by arginine.
[0021] In one embodiment, the half maximum inhibitory concentration (WMC) value of the receptor-binding domain obtained from botulinum toxin heavy chain competitive analysis may be less than the WMC value of the wild-type receptor-binding domain.
[0022] The recombinant polypeptide according to an embodiment of the present invention may further include a light chain domain and a translocation domain, and has greater potency, higher safety, or a longer half-life than wild-type botulinum toxin type A. The recombinant polypeptide may include at least one recombinant botulinum toxin selected from SEQ ID NO: 8 to SEQ ID NO: 32, SEQ ID NO: 43, and SEQ ID NO: 44.
[0023] According to one embodiment of the present invention, the recombinant polypeptide may include a receptor-binding domain of type A1 botulinum toxin, and the receptor-binding domain may include amino acid mutations at two or more positions selected from N954, Y1117, T1232, R1273, and L1278. The receptor-binding domain may include two or more amino acid mutations selected from N954S, Y1117F, T1232R, R1273K, and L1278F. The receptor-binding domain may include amino acid mutations at two or more positions selected from N954S, T1232R, and L1278F. Amino acid mutations in the receptor-binding domain may include N954S and T1232R; N954S and L1278F; T1232R and L1278F; T1232R and R1273K; R1273K and L1278F; N954S, T1232R, and L1278F; Y1117F, R1273K, and L1278F; or T1232R, R1273K, and L1278F.
[0024] According to one embodiment of the present invention, the recombinant polypeptide may include a receptor-binding domain of type A1 botulinum toxin, wherein the half-maximum inhibitory concentration (MCMC) value of the receptor-binding domain variant obtained from botulinum toxin heavy chain competitive analysis may be less than the MMC value of the wild-type receptor-binding domain. The receptor-binding domain variant may include an amino acid mutation at at least one position selected from the group consisting of N880, N954, M968, T990, Q991, N1025, N1026, N1052, T1063, H1064, W1068, N1090, Y1117, S1142, T1232, and L1278. Variants of the receptor-binding domain may include at least one amino acid mutation selected from the group consisting of N880S, N954S, M968I, T990N, Q991K, N1025T, N1026K, N1052K, T1063P, H1064R, W1068M, N1090S, Y1117F, S1142Y, S1142R, S1142I, S1142F, S1142H, T1232R, and L1278F. For example, the receptor-binding domain may include an amino acid mutation at the S1142 position. This amino acid mutation may include S1142Y, S1142R, S1142I, S1142F, or S1142H.
[0025] According to one embodiment of the present invention, recombinant botulinum toxin may include a variant in which one, two or more amino acids of the receptor-binding domain sequence of type A1 botulinum toxin are mutated, said amino acid mutation including one, two or more amino acids selected from the group consisting of N880S, N954S, M968I, T990N, Q991K, N1025T, N1026K, N1052K, T1063P, H1064R, W1068M, N1090S, Y1117F, S1142Y, S1142R, S1142I, S1142F, S1142H, T1232R and L1278F, wherein when administered to a subject requiring treatment, its potency and safety are superior to wild-type type A1 botulinum toxin in at least one aspect, and the remaining aspects are at least equal to wild-type toxin. The recombinant botulinum toxin may include a light chain domain selected from the group consisting of the A1 type botulinum toxin light chain, the A4 type botulinum toxin light chain, and their variants. Furthermore, the recombinant botulinum toxin may also include the aforementioned translocation domain. Compared to wild-type A1 type botulinum toxin, the recombinant botulinum toxin, when administered to individuals, can provide a safer treatment margin; and DAS AUC or CMAP AACThe recombinant botulinum toxin exhibits superior values in one or more of the following, and the remaining values are at least equal to those of the wild-type toxin. For example, compared to wild-type A1 botulinum toxin, the recombinant botulinum toxin can achieve a higher safety margin when administered to an individual; and DAS AUC or CMAP AAC The value is higher in one or more of the following, and the remaining values are at least equal to those of the wild-type toxin.
[0026] According to one embodiment of the present invention, recombinant botulinum toxin may include a variant of the light chain of type A botulinum toxin and a receptor-binding domain, wherein the receptor-binding domain includes one or more amino acid mutations selected from the group consisting of N880S, N954S, M968I, T990N, Q991K, N1025T, N1026K, N1052K, T1063P, H1064R, W1068M, N1090S, S1142Y, S1142R, S1142I, S1142F, S1142H, Y1117F, T1232R, and L1278F. The receptor-binding domain may include recombinant polypeptides of SEQ ID NO: 1 to 7, SEQ ID NO: 33 to 42, and SEQ ID NO: 45 to 49.
[0027] The recombinant botulinum toxin may include light chain domains selected from the group consisting of the A1 type botulinum toxin light chain, the A2 type botulinum toxin light chain, and their variants. When administered to subjects requiring treatment, the recombinant botulinum toxin exhibits superior safety and duration of action, or one or more, compared to wild-type A1 botulinum toxin, with the remaining aspects being at least equivalent to wild-type toxin. Compared to wild-type A1 botulinum toxin, the recombinant botulinum toxin provides a safer treatment margin when administered to individuals; and DAS AUC or CMAP AAC It shows a higher value in one or more of the following:
[0028] According to one embodiment of the present invention, the recombinant polypeptide may include an A1 type botulinum toxin translocation domain. The translocation domain may include amino acid mutations at one or more positions, where the mutations are conserved common amino acids in A2 and A6 botulinum toxins, but different amino acids at the corresponding positions in the A1 type botulinum toxin.
[0029] The amino acid mutation position of the translocation domain may include one or more amino acid mutations selected from the group consisting of L681, D696, I713, K730, E734, K779, N789, G804, E809, L815, K816, and A818. The translocation domain may include one or more amino acid mutations selected from the group consisting of L681I, D696N, I713T, K730E, E734K, K779S, N789D, G804A, E809K, L815V, K816R, and A818V. Recombinant botulinum toxin including the translocation domain can exhibit a superior specific potency compared to wild-type botulinum toxin.
[0030] Beneficial effects According to the present invention, a recombinant polypeptide comprising type A1 botulinum toxin or its subdomains is provided. Attached Figure Description
[0031] Figure 1 This is a graph showing the midpoint temperature (Tm) of thermal denaturation for botulinum toxin type A products (BoNT / A) and recombinant botulinum toxins of SEQ ID NO: 10, 11, 12, 13, 14, 16, and 20.
[0032] Figure 2 This is a graph showing the change in digit abduction score (DAS) over time after administration of botulinum toxin type A (BoNT / A) and recombinant botulinum toxin (SEQ ID NO: 10) to the right gastrocnemius muscle of mice at doses of 1.2 U / kg, 4 U / kg, and 12 U / kg. The DAS values on each test day were analyzed using the Mann-Whitney test. p<0.05, p<0.01).
[0033] Figure 3 This is a graph showing the change in DAS values over time after administration of botulinum toxin type A (BoNT / A) and recombinant botulinum toxin (SEQ ID NO: 11) to the right gastrocnemius muscle of mice at doses of 1.2 U / kg, 4 U / kg, and 12 U / kg. The DAS values on each measurement day were analyzed using the Mann-Whitney test. a p=0.065, b p=0.093).
[0034] Figure 4This is a graph (A) showing the change in DAS values over time after administration of 12 U / kg of botulinum toxin type A (BoNT / A) and recombinant botulinum toxins of SEQ ID NO: 10 and 11 to the right gastrocnemius muscle of rats, and a graph (B) showing the compound muscle action potential (CMAP) values of the left gastrocnemius muscle on day 7 after administration. DAS values on each measurement day were analyzed using the Mann-Whitney test, and CMAP values were analyzed using a two-tailed t-test. p<0.05, a p=0.065).
[0035] Figure 5 This is a graph showing the change in DAS values over time after administration of botulinum toxin type A (BoNT / A) and recombinant botulinum toxins of SEQ ID NO: 22 and 23 to the right gastrocnemius muscle of mice at doses of 1.2 U / kg, 4 U / kg, and 12 U / kg. The DAS values on each measurement day were analyzed using the Mann-Whitney test. p <0.05, a p =0.065, b p =0.082).
[0036] Figure 6 This is a graph showing the CMAP values at the application site (ipsilateral) and non-application site (contralateral) on day 7 after administration of a 12 U / kg dose of botulinum toxin type A (BoNT / A) and recombinant botulinum toxins of SEQ ID NO: 22, 23 to the right gastrocnemius muscle of mice. The CMAP values of botulinum toxin type A and recombinant botulinum toxin were analyzed using a two-tailed t-test based on the application site. p <0.05, p <0.01).
[0037] Figure 7 This is a graph showing the change in DAS values over time after administration of botulinum toxin type A (BoNT / A) and recombinant botulinum toxins of SEQ ID NO: 14 and 15 to the right gastrocnemius muscle of mice at doses of 1.2 U / kg, 4 U / kg, and 12 U / kg. The DAS values on each measurement day were analyzed using the Mann-Whitney test. p <0.05, p<0.01, a p =0.065, b p =0.093).
[0038] Figure 8 This is a graph showing the CMAP values at the application site (ipsilateral) and non-application site (contralateral) on day 7 after administration of a 12 U / kg dose of botulinum toxin type A (BoNT / A) and recombinant botulinum toxins of SEQ ID NO: 14 and 15 to the right gastrocnemius muscle of mice. The CMAP values of botulinum toxin type A and recombinant botulinum toxin were analyzed using a two-tailed t-test based on the application site. p <0.05, p <0.01, p <0.001).
[0039] Figure 9 This is a graph showing the change in DAS values over time after administration of botulinum toxin type A (BoNT / A) and recombinant botulinum toxins of SEQ ID NO: 12 and 13 to the right gastrocnemius muscle of mice at doses of 1.2 U / kg, 4 U / kg, and 12 U / kg. The DAS values on each measurement day were analyzed using the Mann-Whitney test. a p =0.065).
[0040] Figure 10 This is a graph showing the CMAP values at the application site (ipsilateral) and non-application site (contralateral) on day 7 of week 1 after administration of a 12 U / kg dose of botulinum toxin type A product (BoNT / A) and recombinant botulinum toxins of SEQ ID NO: 12 and 13 to the right gastrocnemius muscle of mice. The CMAP values of botulinum toxin type A and recombinant botulinum toxin were analyzed using a two-tailed t-test based on the application site. p <0.05).
[0041] Figure 11 This is a graph showing the change in DAS values over time after administration of botulinum toxin type A (BoNT / A) and recombinant botulinum toxin of SEQ ID NO: 16 to the right gastrocnemius muscle of mice at doses of 1.2 U / kg, 4 U / kg, and 12 U / kg. The DAS values on each measurement day were analyzed using the Mann-Whitney test. p<0.05, a p =0.065, b p =0.093).
[0042] Figure 12 This is a graph showing the CMAP values at the application site (ipsilateral) and non-application site (contralateral) on week 1 (day 6) after administration of a 12 U / kg dose of botulinum toxin type A (BoNT / A) and recombinant botulinum toxin of SEQ ID NO: 16 to the right gastrocnemius muscle of mice. The CMAP values of botulinum toxin type A and recombinant botulinum toxin were analyzed using a two-tailed t-test based on the application site. p <0.01). Detailed Implementation
[0043] The technical and scientific terms used in this specification have the same meanings as those commonly used in the relevant technical field, unless otherwise expressly defined. For ease of understanding, the following definitions should apply: singular expressions include plural expressions, unless the context clearly indicates otherwise.
[0044] The term "and / or" includes all possible combinations of the relevant constituent elements.
[0045] When interpreting constituent elements, they are interpreted as including tolerance ranges, even if no other explicit statement is provided. In this specification, the term "about" is used to include ranges of permissible tolerances conventional in the art. For example, the term "about" may refer to a maximum permissible tolerance of 5%, 10%, 15%, or 20% within a given value or range of values.
[0046] The terms “protein” and “peptide” as used herein are used interchangeably to refer to polymers containing amino acid residues and their variants and synthetic analogs. These terms apply to naturally occurring amino acid polymers, including those containing one or more synthetic, non-naturally occurring amino acids (e.g., chemical analogs of the relevant natural amino acids). These terms also include post-translational modifications of peptides, such as glycosylation, phosphorylation, and acetylation.
[0047] The term "botulinum toxin (BoNT)" encompasses any polypeptide or fragment of botulinum toxin. In one embodiment, botulinum toxin refers to full-length botulinum toxin or botulinum toxin-derived fragments. In a specific embodiment, botulinum toxin can enter neurons and perform a global cellular mechanism that inhibits neurotransmitter release.
[0048] In this specification, “botulinum toxin” includes all serotypes and their variants or fusion proteins, unless otherwise specified.
[0049] For example, botulinum toxins can be selected from the group consisting of type A (BoNT / A), type B (BoNT / B), type C (BoNT / C), type D (BoNT / D), type E (BoNT / E), type F (BoNT / F), type G (BoNT / G), type H (BoNT / H), type X (BoNT / X), enterococcal botulinum toxin J (eBoNT / J), and mosaic botulinum toxins and / or their variants. Examples of mosaic toxins include BoNT / DC, BoNT / CD, and BoNT / FA. For example, type A can be used.
[0050] In one embodiment, the botulinum toxin is derived from various BoNT / A subtypes, such as A1, A2, A3, A4, A5, A6, A7, A9, and A10; BoNT / B subtypes, such as B1, B2, B3, B4, B5, B6, B7, B8, Bnp, and Bbv; BoNT / C subtypes, such as C and CD; BoNT / D subtypes, such as D and DC; BoNT / E subtypes, such as E1, E2, E3, E4, E5, E6, E7, E8, and E9; BoNT / F subtypes, such as F1, F2, F3, F4, F5, F6, and F7; and BoNT / G subtypes, such as subtype G. BoNT subtypes include chimeric BoNTs, such as BoNT / DC, BoNT / CD, and BoNT / FA.
[0051] In this specification, the recombinant botulinum toxin of one embodiment or the various domains constituting the recombinant botulinum toxin (e.g., light chain, heavy chain, subdomains of the light chain, translocation domains of the heavy chain, receptor-binding domains of the heavy chain, etc.) can be recombinant polypeptides derived from any serotype, unless otherwise specifically limited.
[0052] In one embodiment, the term "variant" of botulinum toxin (including wild-type toxin and recombinant toxin) may refer to a botulinum toxin having 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 99.8% or more homology to the sequence of a benchmark botulinum toxin. For example, the term "variant" of botulinum toxin (including wild-type toxin and recombinant toxin) may refer to a botulinum toxin having 1 to 10, 1 to 7, 1 to 5, 1 to 3, or 1 amino acid mutation in the sequence of a benchmark botulinum toxin, such as having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid mutations. In one embodiment, amino acid mutations include both conserved and non-conserved mutations. For example, it may include a conserved mutation in which the amino acid is mutated but its properties (hydrophilicity, hydrophobicity, etc.) are preserved after the mutation.
[0053] For example, the recombinant polypeptide of the present invention may include a variant of type A1 botulinum toxin as a receptor-binding domain, but when the recombinant polypeptide of an embodiment includes a light chain (and its domains) and / or a translocation domain, it may include type A1 botulinum toxin, serotypes other than type A1, and their variants.
[0054] One embodiment of the recombinant botulinum toxin can be a non-complex botulinum toxin that does not contain the complex protein. For example, the non-complex botulinum toxin may not contain non-toxic non-hemagglutinin (NTNH) or hemagglutinin, in which case the molecular weight of the non-complex botulinum toxin may be approximately 150 kDa. In this specification, the non-complex botulinum toxin may be referred to as 7S botulinum toxin or botulinum toxin with a molecular weight of 150 kDa.
[0055] One embodiment of the recombinant botulinum toxin can also be a complex botulinum toxin composition containing a complex protein. For example, the complex botulinum toxin may contain NTNH or hemagglutinin, in which case the molecular weight of the complex botulinum toxin may be approximately 900 kDa or 500 kDa.
[0056] One embodiment of the recombinant botulinum toxin composition may be a composition free of animal protein. For example, one embodiment of the recombinant botulinum toxin composition may be free of animal-derived protein stabilizers. In one embodiment, the recombinant botulinum toxin composition may be free of albumin, such as human serum albumin or recombinant human albumin.
[0057] The terms “unit”, “unit(s)”, or “U” used in this manual refer to LD. 50Dosage is defined as the amount of botulinum toxin that causes 50% death in mice injected with botulinum toxin. The above terms may be used interchangeably within a product.
[0058] "Pharmaceutical composition" refers to a formulation containing an active ingredient. The term "formulation" means that the pharmaceutical composition contains at least one additional ingredient besides the active ingredient (e.g., botulinum toxin), such as albumin (e.g., human serum albumin or recombinant human albumin) and / or sodium chloride. The pharmaceutical composition is a formulation suitable for administration to subjects such as human patients. The pharmaceutical composition may be in lyophilized form, for example, a solution formed after reconstitution of the lyophilized pharmaceutical composition with physiological saline or water, or a solution form that does not require reconstitution. The pharmaceutical composition may be liquid or solid. Animal-derived proteins and / or albumin may be absent from the pharmaceutical composition.
[0059] The term "active ingredient" refers to a substance in a formulation or composition that is biologically or physiologically effective. Specifically, in pharmaceutical formulations or compositions, the term "active ingredient" refers to a component that exhibits the desired pharmaceutical effect. For example, the active ingredient of this invention may be a non-complex botulinum toxin that does not contain a complex protein.
[0060] "Administration" or "conducting administration" refers to the step of providing a pharmaceutical composition or active ingredient to a subject. Pharmaceutical compositions can be administered via various appropriate routes.
[0061] On one hand, the drug composition can be administered transdermally, subcutaneously, or intramuscularly. In specific embodiments, the drug composition can be administered by applying it locally to muscles or muscle groups. For example, forehead wrinkles and skin wrinkles can be reduced by transdermally or subcutaneously applying the composition to the corresponding wrinkle area. For example, the composition according to one embodiment can be administered by subcutaneous or intramuscular injection. The composition according to one embodiment can be administered by subcutaneous or intramuscular injection using a pre-filled syringe. The composition according to one embodiment can be administered transdermally using a transdermal patch or microneedle.
[0062] "Pharmaceutical composition" refers to a formulation containing an active ingredient. In addition to the active ingredient (e.g., botulinum toxin), a "pharmaceutical composition" may include at least one additional ingredient, such as albumin (e.g., human serum albumin or recombinant human albumin) and / or sodium chloride. The pharmaceutical composition is a formulation suitable for administration to subjects, including mammals such as humans. The subjects of administration of the compositions of this application include, but are not limited to, humans or animals, such as humans, pigs, dogs, cats, cattle, horses, rats, etc.
[0063] The pharmaceutical composition may be in liquid or lyophilized form. If the pharmaceutical composition is a lyophilized preparation, it may be reconstituted using, for example, physiological saline or water. The pharmaceutical composition may be in solution form. The pharmaceutical composition may be liquid or solid. Animal-derived proteins and / or albumin may be absent from the pharmaceutical composition.
[0064] "To treat," "therapeutic," or "treatment" means, for example, reducing or diminishing (including partial reduction, significant reduction, near-complete reduction, and complete reduction), resolving, or preventing (temporary or permanent) a disease, obstacle, or abnormality by healing injured or damaged tissue or by altering, modifying, strengthening, improving, enhancing, and / or beautifying an existing or known disease, obstacle, or abnormality to achieve a therapeutic goal. In this specification, "treatment" includes the concept of prevention. "Prevention" means delaying the onset of a disease, obstacle, or condition. Complete prevention is considered achieved when the onset of a disease, obstacle, or condition is delayed within a predetermined timeframe.
[0065] In one embodiment, "treatment" refers to the treatment of a disease, disorder, or pathological condition in a patient, such as a mammal (especially a human), including one or more of the following: (a) To prevent the occurrence of the above-mentioned diseases, disorders or pathological conditions, that is, to prevent the recurrence of the above-mentioned diseases or pathological conditions, or to provide prophylactic treatment for patients who are pre-disposed to the above-mentioned diseases or pathological conditions. (b) Ameliorating the aforementioned disease, disorder or pathological condition, i.e., eliminating or regressing the aforementioned disease, disorder or pathological condition in the patient, including antagonizing the effects of other therapeutic agents; (c) Suppressing the aforementioned disease, disorder, or pathological state, that is, slowing or preventing the progression of the aforementioned disease, disorder, or pathological state in the patient; or (d) Relieve the symptoms of the patient’s above-mentioned disease, disorder or pathological condition.
[0066] The terms “unit”, “unit(s)”, or “U” used in this instruction manual refer to the LD50 dose, defined as the amount of botulinum toxin that causes 50% death in mice injected with botulinum toxin. These terms may be used interchangeably within a product.
[0067] On the one hand, the therapeutically effective doses of botulinum toxin are approximately 0.01 U / kg to approximately 100 U / kg, approximately 0.1 U / kg to approximately 100 U / kg, approximately 0.2 U / kg to approximately 100 U / kg, approximately 0.2 U / kg to approximately 50 U / kg, approximately 0.2 U / kg to approximately 30 U / kg, approximately 0.2 U / kg to approximately 10 U / kg, approximately 0.2 U / kg to approximately 1 U / kg, approximately 1.2 U / kg, approximately 4 U / kg, or approximately 12 U / kg. On the other hand, based on an adult weighing 60 kg, the amounts could be approximately 1 U to approximately 10,000 U, approximately 1 U to approximately 5,000 U, approximately 1 U to approximately 2,500 U, approximately 1 U to approximately 1,000 U, approximately 1 U to approximately 500 U, approximately 1 U to approximately 300 U, approximately 1 U to approximately 200 U, approximately 10 U to approximately 200 U, approximately 10 U to approximately 100 U, or approximately 10 U to approximately 50 U.
[0068] In this invention, "free of animal protein" means that it substantially does not contain proteins derived from animals (e.g., human serum albumin).
[0069] The composition according to one embodiment can be administered in a therapeutically effective amount. As used herein, the term "effective amount" or "therapeutically effective amount" refers to an amount sufficient to treat or prevent disease given a reasonable benefit / risk ratio applicable to any medical treatment or prevention. The effective dose level can be determined based on the severity of the disease, drug activity, the patient's age, weight, health status, and sex, drug sensitivity, timing of administration, route of administration, and the rate of elimination of the disclosed composition, duration of treatment, drugs used concurrently or in combination with the disclosed composition, and other factors known in the medical field.
[0070] In one embodiment, botulinum toxin can be administered in a single or multiple treatment sessions. The dosage can be administered via a single injection or multiple injections at the injection site. In multiple treatment sessions, botulinum toxin can be administered at intervals of 6 months, 4 months, or 3 months or less. The interval between botulinum toxin administrations in multiple treatment sessions includes the initial treatment and a second treatment, where the dose of the second treatment can be less than, greater than, or equal to the dose of the initial treatment.
[0071] Botulinum toxin can be produced by bacteria or through recombination.
[0072] Botulinum toxin includes botulinum toxin derivatives. Botulinum toxin derivatives can be derivatives that include one or more chemical or functional modifications on a portion or part of the chain of natural botulinum toxin or recombinant native botulinum toxin having botulinum toxin activity. For example, botulinum toxin derivatives can be modified toxins having one or more missing, modified, or substituted amino acids. Botulinum toxin can be a recombinant peptide, a fusion protein, or a hybrid neurotoxin, for example, made from subunits or domains of different toxin serotypes. Botulinum toxin can be part of a complete molecule with toxic activity and can be utilized as part of its combinatorial or conjugated molecules (e.g., fusion proteins).
[0073] The term "domain" refers to a conserved portion of a given protein sequence, which is a tertiary structure that can evolve, function, and exist independently of the rest of the protein chain.
[0074] Because the domains are independent and stable, chimera proteins can be generated by exchanging domains between one protein and another through genetic engineering.
[0075] The term "homology" refers to the degree of similarity in the amino acid sequences between polypeptides. For example, when the first amino acid sequence is identical to the second amino acid sequence, the first and second amino acid sequences exhibit 100% homology.
[0076] The term "recombination" refers to the process by which the elements that make up genes, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), rearrange their sequences in a manner different from the original during disassembly and reassembly. DNA fragments can be artificially recombined through molecular biology experiments. The artificially recombined DNA described above is called recombinant DNA.
[0077] A recombinant polypeptide according to an embodiment of the present invention may include a receptor binding domain (RBD) of type A1 botulinum toxin. The receptor binding domain may include amino acid mutations. The receptor binding domain may include amino acid mutations at one or more positions, said positions being conserved common amino acids in type A2 and type A6 botulinum toxins, but different amino acids at the corresponding positions in type A1 botulinum toxin.
[0078] For example, the amino acid mutation may be the replacement of at least a portion of the A1 type botulinum toxin sequence with an amino acid sequence common to both A2 and A6 type botulinum toxins. For example, asparagine, which is the 880th amino acid in the receptor-binding domain of A1 type botulinum toxin, may be replaced by serine, which is the 880th amino acid in both A2 and A6 type botulinum toxins.
[0079] For example, the amino acid mutation may be the replacement of at least a portion of the amino acid sequence of type A1 botulinum toxin with an amino acid other than that shared by types A2 and A6 botulinum toxin. For example, asparagine, which is the 880th amino acid in the receptor-binding domain of type A1 botulinum toxin, may be replaced by an amino acid other than serine, which is the 880th amino acid in both type A2 and type A6 botulinum toxin (e.g., a natural amino acid, its stereoisomer, or its variants).
[0080] For example, the asparagine at position 880 in the receptor-binding domain of type A1 botulinum toxin can be conservatively replaced by other amino acids (e.g., threonine or glutamine).
[0081] The recombinant polypeptide of one embodiment may include an amino acid mutation, such as one, two, or three, of at least one sequence selected from the group consisting of N880, W1068, and N1090. For example, the receptor-binding domain may include an amino acid mutation, such as one, two, or three, of one or more sequences selected from the group consisting of N880S, W1068M, and N1090S. The amino acid mutation may be independently selected from deletion, modification, and substitution. For example, an amino acid mutation may be a substitution.
[0082] The receptor-binding domain may also include an amino acid mutation of at least one sequence selected from the group consisting of N954, M968, T990, Q991, N1025, N1026, N1052, T1063, H1064, Y1117, T1232, and L1278, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12. For example, the receptor-binding domain may also include an amino acid mutation of at least one sequence selected from the group consisting of N954S, M968I, T990N, Q991K, N1025T, N1026K, N1052K, T1063P, H1064R, Y1117F, T1232R, and L1278F, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12.
[0083] The receptor-binding domain may also include amino acid mutations of at least one sequence selected from the group consisting of N954, M968, T990, Q991, N1025, N1026, N1052, T1232, and L1278, for example, 1, 2, 3, 4, 5, 6, 7, 8, or 9. For example, the receptor-binding domain may include amino acid mutations of at least one sequence selected from the group consisting of N954S, M968I, T990N, Q991K, N1025T, N1026K, N1052K, T1232R, and L1278F, for example, 1, 2, 3, 4, 5, 6, 7, 8, or 9.
[0084] For example, the receptor-binding domain may include N954S, M968I, T990N, Q991K, N1025T, N1026K, N1052K, T1232R, and L1278F, and may include at least one or two or more amino acid mutations selected from the group consisting of T1063P, H1064R, and Y1117F. For example, the receptor-binding domain may include amino acid mutations of N954S, M968I, T990N, Q991K, N1025T, N1026K, N1052K, T1232R, and L1278F, and may include amino acid mutations of "T1063P and H1064R" or "Y1117F".
[0085] The receptor-binding domain may also include amino acid mutations at one or more positions other than those that are conserved common amino acids in type A2 and type A6 botulinum toxins, but different amino acids at the corresponding positions in type A1 botulinum toxin. For example, the receptor-binding domain may also include an amino acid mutation at position S1142. For example, the amino acid mutation may also include S1142Y, S1142R, S1142I, S1142F, or S1142H.
[0086] In addition, the positions of the nine amino acids that can be mutated are determined by selecting sequences common to both type A2 and type A6 botulinum toxin sequences that are different from those of type A1 botulinum toxin.
[0087] In one embodiment, the receptor-binding domain may include mutations in the amino acid sequences of N880, W1068, and N1090, as well as N954, M968, T990, Q991, N1025, N1026, N1052, T1232, and L1278.
[0088] In one embodiment, the receptor-binding domain may include mutations in the amino acid sequences of N880S, W1068M, and N1090S, as well as N954S, M968I, T990N, Q991K, N1025T, N1026K, N1052K, T1232R, and L1278F.
[0089] In one embodiment, the receptor-binding domain may include one of SEQ ID NO: 1 to 7 and 33 to 42.
[0090] Amino acid mutations can be selected independently from deletions, modifications, and substitutions. For example, an amino acid mutation can be a substitution.
[0091] A recombinant polypeptide according to an embodiment of the present invention may include a translocation domain of recombinant A1 botulinum toxin. The recombinant A1 botulinum toxin translocation domain may include amino acid mutations at one or more positions, where the positions are conserved common amino acids in A2 and A6 botulinum toxins, but different amino acids at the corresponding positions in the A1 botulinum toxin. For example, the amino acid mutation positions of the recombinant translocation domain in one embodiment may include at least one selected from the group consisting of L681, D696, I713, K730, E734, K779, N789, G804, E809, L815, K816, and A818. For example, the recombinant translocation domain of one embodiment may include at least one amino acid mutation selected from the group consisting of L681I, D696N, I713T, K730E, E734K, K779S, N789D, G804A, E809K, L815V, K816R, and A818V.
[0092] Alternatively, the recombinant translocation domain of one embodiment may include the translocation domain of type A1 botulinum toxin, and may include at least one amino acid mutation at a position selected from the group consisting of D589, E734, and E809. For example, the recombinant translocation domain of one embodiment may include the translocation domain of type A1 botulinum toxin, and may include at least one amino acid mutation at a position selected from the group consisting of D589K, E734K, and E809K.
[0093] In one embodiment, the translocation domain may include or be constituted by a translocation domain of wild-type A1 botulinum toxin, or may include or be constituted by a translocation domain of A1 botulinum toxin, wherein the A1 botulinum toxin includes at least one amino acid mutation selected from the group consisting of D589K, L681I, D696N, I713T, K730E, E734K, K779S, N789D, G804A, E809K, L815V, K816R, A818V, E734K, and E809K.
[0094] In one embodiment of the invention, the recombinant polypeptide (e.g., a recombinant receptor-binding domain) may further include a translocation domain. The translocation domain may include a polypeptide selected from the group consisting of translocation domains of type A1 botulinum toxin, type A2 botulinum toxin, type A6 botulinum toxin, and variants thereof (e.g., the recombinant translocation domain of the aforementioned recombinant type A1 botulinum toxin). For example, the translocation domain may include a polypeptide selected from the group consisting of translocation domains of type A2 botulinum toxin, type A6 botulinum toxin, and variants thereof. For example, the translocation domain may include a translocation domain of type A2 botulinum toxin or a translocation domain of type A6 botulinum toxin.
[0095] One embodiment of the recombinant polypeptide may include the aforementioned recombinant receptor-binding domain and / or the aforementioned recombinant translocation domain. In one embodiment, the recombinant polypeptide includes the aforementioned receptor-binding domain of botulinum toxin type A1 and... The recombinant polypeptide of one embodiment may further include a light chain domain. The light chain domain may be a recombinant polypeptide. For example, the light chain domain may include a polypeptide selected from the group consisting of type A1 botulinum toxin, type A4 botulinum toxin, and variants thereof. For example, the light chain domain may include a subdomain of type A1 botulinum toxin or a variant thereof, or a subdomain of type A4 botulinum toxin or a variant thereof. Variants of each subdomain of type A1 or type A4 botulinum toxin may have 99.8% or higher, 99.5% or higher, 99% or higher, 98% or higher, 97% or higher, 96% or higher, 95% or higher, 95% or higher, 93% or higher, 92% or higher, 91% or higher, or 90% or higher homology to the sequence of each subdomain of wild-type type A1 or type A4 botulinum toxin. For example, variants of the subdomains of type A1 or type A4 botulinum toxin may include 1, 2, 3, 4, 5, 6, 7, 8 or 9 amino acid mutations in the sequence of the subdomains of wild-type type A1 or type A4 botulinum toxin.
[0096] In one embodiment, the sequences of the A1 and A4 botulinum toxin light chains are divided into first, second, third, and fourth domains according to the following criteria.
[0097] The first domain of the A1 type botulinum toxin light chain and the first domain of the A4 type botulinum toxin light chain are defined as the portion including the α-exosite, which is the site that primarily interacts with synaptosome-associated protein 25 (SNAP25), which serves as the substrate. The first domain of the A1 and A4 type botulinum toxin light chains may include amino acids from position 1 to position 20 to position 90 to position 150, for example, amino acids from position 1, 5, 10, 15, or 20 to position 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150.
[0098] In one embodiment, the first domain of the A1 type botulinum toxin light chain and the first domain of the A4 type botulinum toxin light chain include a site that interacts with the substrate SNAP25 as a portion comprising an α-exosite, and may include amino acids at positions 1, 5, 10, 15, or 20 up to positions 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150. Amino acids, such as amino acids at positions 20 to 90, 20 to 100, 20 to 110, 20 to 120, 20 to 130, 20 to 140, 10 to 90, 10 to 100, 10 to 110, 10 to 120, 10 to 130, or 10 to 140. For example, the first domain of the A1 type botulinum toxin light chain and the first domain of the A4 type botulinum toxin light chain may include amino acids at positions 1 to 120.
[0099] The second domain of the A1 type botulinum toxin light chain and the second domain of the A4 type botulinum toxin light chain are defined as the part that is mainly involved in light chain enzyme activity, including 170 loops, and is the part that binds to zinc as a cofactor. The second domain of the light chain of type A1 and type A4 botulinum toxins may include amino acids from position 91 to 151 (e.g., amino acids at positions 91, 96, 101, 106, 111, 116, 121, 126, 131, 136, 141, 146, and 151) to position 210 to 270 (e.g., amino acids at positions 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, and 270).
[0100] In one embodiment, the second domains of the A1 type botulinum toxin light chain and the A4 type botulinum toxin light chain participate in the enzymatic activity of the light chain, including a 170-loop and a site for binding with zinc as a cofactor, and may include amino acids from positions 91, 96, 101, 106, 111, 116, 121, 126, 131, 136, 141, 146, and 151 to positions 210, 215, and 220. The amino acids at positions 225, 230, 235, 240, 245, 250, 255, 260, 265, and 270, for example, amino acids at positions 91 to 270, 101 to 260, 111 to 250, 121 to 240, 131 to 230, 141 to 220, or 151 to 210. For example, the second domain of the A1 type botulinum toxin light chain and the second domain of the A4 type botulinum toxin light chain may include amino acids at positions 121 to 240.
[0101] The third domain of the A1 type botulinum toxin light chain and the third domain of the A4 type botulinum toxin light chain are defined as domains that include 250 loops and 370 loops for stabilizing substrate binding, and domains that include α-exosite and β-exosite sites, both of which participate as substrate binding sites. The third domain of the light chain of type A1 and type A4 botulinum toxin may include amino acids from position 211 to 271 (e.g., amino acids at positions 211, 216, 221, 226, 231, 236, 241, 246, 251, 256, 261, 266, and 271) to position 386 to 446 (e.g., amino acids at positions 386, 391, 396, 401, 406, 411, 416, 421, 426, 431, 436, 441, and 446).
[0102] The third domain of the A1 type botulinum toxin light chain and the third domain of the A4 type botulinum toxin light chain include 250 loops and 370 loops for stabilizing substrate binding, and include α-exosite and β-exosite sites that both participate as substrate binding sites, and may include positions 211, 216, 221, 226, 231, 236, 241, 246, 251, 256, 261, 266, and 271. Amino acids up to positions 386, 391, 396, 401, 406, 411, 416, 421, 426, 431, 436, 441, and 446, for example, amino acids from positions 211 to 446, 221 to 436, 231 to 426, 241 to 416, 251 to 406, or 261 to 396. For example, the third domain of the A1 type botulinum toxin light chain and the third domain of the A4 type botulinum toxin light chain may include amino acids from positions 241 to 396.
[0103] The fourth domain (SEQ ID NO: 4) of the A1 type botulinum toxin light chain and the fourth domain (SEQ ID NO: 8) of the A4 type botulinum toxin light chain can be defined as domains that include the parts involved in the structural flexibility of the A type botulinum toxin light chain. The fourth domain of the light chain of type A1 and type A4 botulinum toxins may include amino acids from positions 362 to 425 (e.g., amino acids at positions 362, 367, 372, 377, 382, 387, 392, 397, 402, 407, 412, 417, 422, and 425) to positions 410 to 448 (e.g., amino acids at positions 410, 414, 417, 420, 425, 430, 435, 440, 445, and 448).
[0104] In one embodiment, the fourth domain (SEQ ID NO: 4) of the A1 type botulinum toxin light chain and the fourth domain (SEQ ID NO: 4) of the A4 type botulinum toxin light chain... NO: 8) Includes the site involved in the structural flexibility of the light chain of botulinum toxin type A, and may include amino acids from positions 362, 367, 372, 377, 382, 387, 392, 397, 402, 407, 412, 417, 422, and 425 to positions 410, 414, 417, 420, 425, 430, 435, 440, 445, and 448, for example, amino acids from positions 362 to 448, amino acids from positions 372 to 438, or amino acids from positions 382 to 428. For example, the fourth domain of the A1 type botulinum toxin light chain and the fourth domain of the A4 type botulinum toxin light chain may include amino acids from position 397 to position 425.
[0105] The light chain domain can be any of the first, second, third, and fourth domains of the type A botulinum toxin light chain (excluding type A4 botulinum toxin), where the sequence of the third domain is replaced by a sequence of the third domain of type A4 botulinum toxin or a variant thereof. Variants of the third domain of type A4 botulinum toxin can have 99% or higher, 98% or higher, 97% or higher, 96% or higher, 95% or higher, 95% or higher, 93% or higher, 92% or higher, 91% or higher, or 90% or higher homology with the sequence of the third domain of wild-type type A4 botulinum toxin. For example, variants of the third domain of type A4 botulinum toxin can include 1, 2, 3, 4, 5, 6, 7, 8, or 9 amino acid mutations in the sequence of the third domain of wild-type type A4 botulinum toxin. These amino acid mutations can be independently selected from deletions, modifications, and substitutions; for example, an amino acid mutation can be an amino acid substitution. The variants of the fourth domain of type A4 botulinum toxin, the variants of the first domain of type A1 botulinum toxin, the variants of the second domain of type A1 botulinum toxin, and the variants of the fourth domain of the light chain of type A1 botulinum toxin described below are also applicable to the content described for the variants of the third domain of type A4 botulinum toxin. For example, these variants may have 99% or higher, 98% or higher, 97% or higher, 96% or higher, 95% or higher, 95% or higher, 93% or higher, 92% or higher, 91% or higher, or 90% or higher homology with the wild-type domain sequence, and may include 1, 2, 3, 4, 5, 6, 7, 8, or 9 amino acid mutations in the wild-type domain sequence.
[0106] The light chain domains may be, in the first, second, third, and fourth domains of the recombinant type A botulinum toxin light chain, wherein the sequence of the fourth domain is further replaced by the sequence of the fourth domain of type A4 botulinum toxin or a variant thereof. The light chain domains may also be, in the first, second, third, and fourth domains of the non-A1 type botulinum toxin type A light chain, wherein the sequence of the second domain is replaced by the sequence of the second domain of type A1 botulinum toxin or a variant thereof.
[0107] The light chain domains may be, in the first, second, third, and fourth domains of the recombinant type A botulinum toxin light chain, wherein the sequence of the fourth domain is further replaced by a sequence of the fourth domain of type A1 botulinum toxin or a variant thereof. In one embodiment, the light chain domains may include the first and second domains of the type A1 botulinum toxin light chain; or variants thereof. The light chain domains may also include the third and fourth domains of the type A4 botulinum toxin light chain; or variants thereof.
[0108] In one embodiment, a variant of each of the first, second, third, or fourth domains of the type A botulinum toxin light chain may refer to a subdomain of the type A botulinum toxin light chain having 98% or higher homology, or 99% or higher homology, to the first, second, third, or fourth domains of the wild-type type A botulinum toxin light chain, respectively. In another embodiment, a variant of each of the first, second, third, or fourth domains of the type A botulinum toxin light chain may each refer to a subdomain of the type A botulinum toxin light chain having 1 to 10, 1 to 7, 1 to 5, or 1 to 3 amino acid mutations in the first, second, third, or fourth domains of the wild-type type A botulinum toxin light chain, for example, having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations.
[0109] One embodiment of the light chain structural domain may include the recombinant light chain disclosed in PCT-KR2022-008793 or PCT-KR2022-008798, the entire contents of which are incorporated herein by reference.
[0110] One embodiment of the light chain structural domain may include a first and a second structural domain of the wild-type A1 botulinum toxin light chain; or variants thereof, and a third and a fourth structural domain of the wild-type A4 botulinum toxin light chain; or variants thereof.
[0111] When the light chain domain of an embodiment is a variant, the variant of the subdomain may have 99% or higher, 98% or higher, 97% or higher, 96% or higher, 95% or higher, 94% or higher, 93% or higher, 92% or higher, 91% or higher, or 90% or higher homology with the sequence of the light chain subdomain of wild-type botulinum toxin. For example, the variant of the corresponding subdomain may include 1, 2, 3, 4, 5, 6, 7, 8, or 9 amino acid mutations in the sequence of the light chain subdomain of wild-type botulinum toxin.
[0112] When the light chain domain of an embodiment is a variant, it can be a variant in which the third domain of the A4 type botulinum toxin light chain is mutated. For example, a variant of the third domain of A4 type botulinum toxin can have 99% or higher, 98% or higher, 97% or higher, 96% or higher, 95% or higher, 94% or higher, 93% or higher, 92% or higher, 91% or higher, or 90% or higher homology with the sequence of the third domain of wild-type A4 type botulinum toxin. For example, a variant of the third domain of A4 type botulinum toxin can include 1, 2, 3, 4, 5, 6, 7, 8, or 9 amino acid mutations in the sequence of the third domain of wild-type A4 type botulinum toxin. For example, a variant of the third domain of A4 type botulinum toxin can be a variant in which amino acids at positions 260 and / or 264 are mutated based on the full-length light chain domain. For example, a variant of the third domain of type A4 botulinum toxin could be a variant in which leucine at position 260 is replaced by phenylalanine and isoleucine at position 264 is replaced by arginine, based on the full-length light chain domain.
[0113] Provided that the content is not contradictory, the above description of the light chain structural domain can also be applied to the light chain structural domain described later.
[0114] One embodiment of the recombinant receptor binding domain may include one or more sequences selected from SEQ ID NO: 1 to 7, SEQ ID NO: 33 to 42, and SEQ ID NO: 45 to 49.
[0115] The recombinant polypeptide of one embodiment may further include a cell penetrating peptide. In one embodiment, the cell penetrating peptide may be IMT-P8. The cell penetrating peptide of one embodiment may be linked to the recombinant polypeptide via a glycine-serine linker (GS linker). The cell penetrating peptide may be directly or indirectly linked to the recombinant polypeptide via the GS linker.
[0116] A GS linker is an amino acid linker rich in glycine and including glycine and serine. It may include conventional GS linkers used in the field and may be a linker including four or more, or five or more G (Glycine) and S (Serine) links. For example, a GS linker may be GGGGS.
[0117] In one embodiment of the receptor-binding domain, the half-maximum inhibitory concentration (MCIC) value obtained from a botulinum toxin heavy chain competitive analysis may be smaller than that of the wild-type receptor-binding domain. For example, in one embodiment of the receptor-binding domain, the MIC value obtained from a botulinum toxin heavy chain competitive analysis based on an enzyme-linked immunosorbent assay (ELISA) may be smaller than that of the wild-type receptor-binding domain.
[0118] The recombinant polypeptide of one embodiment may further include a light chain domain, the light chain domain including polypeptides selected from the group consisting of botulinum toxin type A1, botulinum toxin type A2, and variants thereof; and may further include a translocation domain, the translocation domain including polypeptides selected from the group consisting of translocation domains of botulinum toxin type A1, translocation domains of botulinum toxin type A2, translocation domains of botulinum toxin type A6, and variants thereof.
[0119] When the translocation domain of an embodiment is a variant, the variant of the translocation domain may have 99.5% or higher, 99% or higher, 98% or higher, 97% or higher, 96% or higher, 95% or higher, 94% or higher, 93% or higher, 92% or higher, 91% or higher, 90% or higher, 89% or higher, 88% or higher, 87% or higher, 86% or higher, or 85% or higher homology with the sequence of the translocation domain of wild-type botulinum toxin (e.g., type A1, type A2, or type A6 botulinum toxin). For example, variants of the corresponding subdomain may include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more amino acid mutations in the sequence of the light chain subdomain of wild-type botulinum toxin, or include 30, 25, 20, 18, 15 or fewer amino acid mutations.
[0120] One embodiment of the translocation domain may include at least one amino acid mutation selected from the group consisting of L681, D696, I713, K730, E734, K779, N789, G804, E809, L815, K816, and A818.
[0121] One embodiment of the translocation domain may include at least one amino acid mutation selected from the group consisting of L681I, D696N, I713T, K730E, E734K, K779S, N789D, G804A, E809K, L815V, K816R, and A818V.
[0122] One embodiment of the translocation domain may include at least one amino acid mutation selected from the group consisting of D589, E734, and E809.
[0123] One embodiment of the translocation domain may include at least one amino acid mutation selected from the group consisting of D589K, E734K, and E809K.
[0124] Compared to wild-type botulinum toxin type A, one embodiment of the recombinant peptide may have greater potency, higher safety, or a longer half-life.
[0125] One embodiment of the recombinant polypeptide may include one or more sequences selected from SEQ ID NO: 1 to 7, SEQ ID NO: 33 to 42, and SEQ ID NO: 45 to 49; SEQ ID NO: 8 to 32, SEQ ID NO: 43 and 44; or SEQ ID NO: 1 to 49, which will be described later in Table 1.
[0126] The recombinant polypeptide according to one embodiment of the present invention may include a receptor-binding domain of botulinum toxin type A1, and the receptor-binding domain may include amino acid mutations at two or more positions selected from N954, Y1117, T1232, R1273, and L1278. For example, the receptor-binding domain may include two or more amino acid mutations selected from N954S, Y1117F, T1232R, R1273K, and L1278F. The receptor-binding domain of one embodiment may include amino acid mutations at two or more positions selected from N954, T1232, and L1278. For example, the receptor-binding domain may include amino acid mutations at two or more positions selected from N954S, T1232R, and L1278F.
[0127] For example, amino acid mutations in the receptor-binding domain can include N954S and T1232R; N954S and L1278F; T1232R and L1278F; T1232R and R1273K; R1273K and L1278F; N954S, T1232R, and L1278F; Y1117F, R1273K, and L1278F; or T1232R, R1273K, and L1278F.
[0128] The recombinant polypeptide according to an embodiment of the present invention may include a receptor-binding domain of type A1 botulinum toxin. In the variants of the receptor-binding domain, the half-maximum inhibitory concentration (MCMC) value obtained from botulinum toxin heavy chain competitive analysis may be less than that of the wild-type receptor-binding domain. The variants of the receptor-binding domain may include an amino acid mutation at at least one position selected from the group consisting of N880, N954, M968, T990, Q991, N1025, N1026, N1052, T1063, H1064, W1068, N1090, Y1117, S1142, T1232, and L1278.
[0129] For example, the receptor-binding domain may include an amino acid mutation at the S1142 position. For example, the amino acid mutation may include S1142Y, S1142R, S1142I, S1142F, or S1142H.
[0130] The recombinant botulinum toxin according to one embodiment of the present invention may include a variant in which two or more amino acids of the receptor-binding domain sequence of type A1 botulinum toxin are mutated. The amino acid mutations may include two or more selected from the group consisting of N880S, N954S, M968I, T990N, Q991K, N1025T, N1026K, N1052K, T1063P, H1064R, W1068M, N1090S, Y1117F, S1142Y, S1142R, S1142I, S1142F, S1142H, T1232R, and L1278F. When administered to subjects requiring treatment, the recombinant botulinum toxin of one embodiment exhibits superior potency and safety compared to wild-type type A1 botulinum toxin, and the remaining properties are at least equivalent to those of the wild-type toxin. For example, compared to wild-type A1 botulinum toxin, one embodiment of recombinant botulinum toxin CMAP or DAS (e.g., CMAP) AUC or DAS AAC The substance is superior to at least one of weight loss or a safety margin, and the remaining substances are at least equivalent to wild-type toxins. In this specification, "equivalent or superior" can mean that the effect of the corresponding value of the example substance is not statistically significantly inferior to that of the corresponding value of the comparison substance.
[0131] According to one embodiment, the recombinant botulinum toxin may include a light chain domain selected from the group consisting of type A1 botulinum toxin light chains, type A2 botulinum toxin light chains, and variants thereof. The above description of the light chain domain can also be applied to the light chain domain.
[0132] For example, the light chain domains of a recombinant botulinum toxin in one embodiment may include a first and a second domain of an A1-type botulinum toxin light chain; or variants thereof, and a third and a fourth domain of an A4-type botulinum toxin light chain; or variants thereof. For example, the first domain of the light chain domains of the recombinant botulinum toxin may include a first domain of an A1-type botulinum toxin light chain or a variant thereof, the second domain may include a second domain of an A1-type botulinum toxin light chain or a variant thereof, the third domain may include a third domain of an A4-type botulinum toxin light chain or a variant thereof, and the fourth domain may include a fourth domain of an A4-type botulinum toxin light chain or a variant thereof.
[0133] For example, a variant of the third domain of type A4 botulinum toxin can be a variant in which amino acids at positions 260 and / or 264 are mutated when the full-length light chain domain is used as a reference. For example, a variant of the third domain of type A4 botulinum toxin can be a variant in which leucine at position 260 is replaced by phenylalanine and isoleucine at position 264 is replaced by arginine when the full-length light chain domain is used as a reference.
[0134] Compared to wild-type A1 botulinum toxin, one embodiment of the recombinant botulinum toxin can achieve a safety margin when administered to individuals; and DAS AUC or CMAP AAC The translocation domain exhibits a superior value among one or more of the following, and the remaining values are at least equal to those of the wild-type toxin. In one embodiment of the recombinant botulinum toxin, the translocation domain may include a polypeptide selected from the group consisting of translocation domains of type A1 botulinum toxin, type A2 botulinum toxin, type A6 botulinum toxin, and variants thereof. In one embodiment, the translocation domain may include at least one amino acid mutation selected from the group consisting of D589, E734, and E809. In one embodiment, the translocation domain may include at least one amino acid mutation selected from the group consisting of D589K, E734K, and E809K.
[0135] One embodiment of the recombinant botulinum toxin may include the above-described type A botulinum toxin light chain variants (e.g., variants of the forms A1-1, A1-2, A4-3, and A4-4) and a receptor-binding domain, wherein the receptor-binding domain includes one or more amino acid mutations selected from the group consisting of N880S, N954S, M968I, T990N, Q991K, N1025T, N1026K, N1052K, T1063P, H1064R, W1068M, N1090S, S1142Y, S1142R, S1142I, S1142F, S1142H, Y1117F, T1232R, and L1278F. One embodiment of the receptor-binding domain may include recombinant polypeptides of SEQ ID NO: 1 to 7, SEQ ID NO: 33 to 42, and SEQ ID NO: 45 to 49. One embodiment of the recombinant botulinum toxin may include a translocation domain comprising one or more amino acid mutations in L260F and I264R.
[0136] A variant light chain of recombinant botulinum toxin of one embodiment may include a first and second domain of an A1 type botulinum toxin light chain; or variants thereof, and a third and fourth domain of an A4 type botulinum toxin light chain; or variants thereof. A light chain domain of one embodiment may include a variant of the second domain of an A1 type botulinum toxin light chain, wherein the leucine at position 260 of the variant of the second domain of the A1 type botulinum toxin light chain is replaced by phenylalanine, and the isoleucine at position 264 is replaced by arginine. Compared to wild-type botulinum toxin, when administered to a patient, the recombinant botulinum toxin of one embodiment may exhibit inhibited diffusion, increased duration of action, and rapid onset of action. Compared to wild-type A1 type botulinum toxin, when administered to an individual, the safety profile and duration of action of the recombinant botulinum toxin of one embodiment may exhibit greater values, and the remaining values are at least equal to those of the wild-type toxin. For example, when administered to an individual, the recombinant botulinum toxin of one embodiment may have a higher safety margin than wild-type A1 type botulinum toxin, and DAS AUC or CMAP AAC It can be equivalent to or higher than wild-type toxins. For example, compared to wild-type A1 botulinum toxin, when administered to an individual, the safety margin of a recombinant botulinum toxin in one embodiment can be equal to or higher, and DAS AUC or CMAP AAC It can be higher than that of wild-type toxins.
[0137] Compared to wild-type botulinum toxin type A (e.g., wild-type A1 botulinum toxin), botulinum toxins comprising the various recombinant peptides described above in this invention can have greater potency, higher safety, or a longer half-life. For example, compared to wild-type botulinum toxin, when administered to a patient, one embodiment of botulinum toxin comprising recombinant peptides can exhibit inhibited diffusion, increased duration of action, and rapid onset of action.
[0138] One embodiment of the botulinum toxin comprising a recombinant polypeptide may include pharmaceutically acceptable excipients or additives. Pharmaceutically acceptable excipients or additives may be stabilizers, ionic compounds, surfactants, buffers, lyophilization protectants, or combinations thereof, such as amino acids (e.g., methionine), salts (e.g., NaCl), buffer solutions, nonionic surfactants (e.g., polysorbates, such as polysorbate 20, poloxamer), sugars (e.g., monosaccharides, sucrose, trehalose, and other disaccharides), sugar alcohols (e.g., sorbitol), or combinations thereof.
[0139] The botulinum toxin composition comprising recombinant polypeptides of the present invention can be formulated into any form, such as a solid or liquid formulation, for example, a lyophilized powder, a liquid, or a pre-filled syringe formulation.
[0140] One embodiment of the present invention provides a composition for improving, preventing or treating a disease, wherein botulinum toxin comprising recombinant polypeptides is used as an active ingredient.
[0141] An embodiment of the present invention provides the use of a botulinum toxin composition administered to an individual to improve or treat a disease, wherein the botulinum toxin composition comprises botulinum toxin containing recombinant polypeptides as the active ingredient.
[0142] An embodiment of the present invention provides a method for improving, preventing or treating a disease by applying a botulinum toxin composition to an individual, wherein the botulinum toxin composition comprises botulinum toxin containing recombinant polypeptides as the active ingredient.
[0143] One embodiment of the present invention provides the use of botulinum toxin comprising recombinant polypeptides in the manufacture of a medicament for improving, preventing or treating a disease.
[0144] In one embodiment, the condition or disease may include wrinkles, square jaw, pointed chin, wound, softening of the skin, scars, acne, pores, elasticity, decreased sebum secretion and / or keloids; and / or facial spasm, eyelid spasm, torticollis, blepharospasm, cervical dystonia, oropharyngeal dystonia, spasmodic speech disorder, migraine, anal pruritus and / or hyperhidrosis.
[0145] In one embodiment of the invention, the botulinum toxin composition comprising the recombinant polypeptide may or may not include animal protein (e.g., albumin such as human serum albumin). When the composition of one embodiment does not include animal protein, amino acids may be included as stabilizers. In one embodiment, the amino acid may be one of the 20 standard amino acids found in nature, but is not limited thereto. The amino acid of one embodiment may be any amino acid known in the art as a stabilizer. For example, in one embodiment, the amino acid may include nonpolar amino acids, such as methionine, isoleucine, and / or tryptophan.
[0146] The present invention will now be described in further detail with reference to embodiments, but these are for illustrative purposes only and are not intended to limit the scope of the invention in any way.
[0147] Example 1: Purification of the domain-substituted type A botulinum toxin heavy chain receptor binding domain A recombinant receptor-binding domain expression vector (cloned into the pET28a vector) was introduced into *E. coli* BL21(DE3) cells, thereby inducing the expression of a domain-replaced recombinant botulinum toxin type A heavy chain receptor-binding domain (RBD) (i.e., the recombinant polypeptide corresponding to the embodiments of the present invention). Expression was induced using isopropyl β-D-thiogalactopyranoside (IPTG). Specifically, after adding IPTG to liquid culture medium, BL21(DE3) cells cultured at an appropriate temperature for an appropriate time were centrifuged to precipitate the cells. The culture medium in the supernatant was removed, and the precipitated cells were resuspended in buffer A (20 mM sodium phosphate, 150 mM NaCl, 10 mM imidazole, pH 7.3). The cells were then lysed on ice using an ultrasonic disperser. After centrifuging the fragmented cells, the recombinant peptides were isolated from the supernatant after cell debris removal using a histidine tag bound to nickel-nitrotriacetic acid (Ni-NTA) resin. The amino acid sequences of the isolated recombinant peptides are shown in Table 1.
[0148] Table 1
[0149] The parentheses in Table 1 show the locations of amino acid mutations in wild-type botulinum toxin and the information of the mutated amino acids. For example, SEQ ID NO: 1 represents a recombinant polypeptide in which the asparagine at position 880 in the receptor-binding domain of wild-type A1 botulinum toxin is replaced by a serine residue.
[0150] Example 2: ELISA-based Botox heavy chain competition assay The purified recombinant peptides of SEQ ID NO: 2, 6, 33, 34, 35 to 43, 45 to 49 were analyzed by competition assay.
[0151] Differentiated Ntera-2 cells (CRL-1973, ATCC) were seeded in 96-well plates and cultured for 4 days at 37°C and 5% CO2 in DMEM / F12 (WelGene) medium supplemented with 5% fetal bovine serum (FBS) (Gibco), B27 (Gibco), and an antibiotic-antimycotic agent (Gibco). After 4 days, the cells were simultaneously treated with 300 U / well of BoNT / A (150 kDa, Medytox, batch number: RBTS2301) and different concentrations of BoNT HC (botulinum toxin heavy chain) for 48 hours. The treatment concentrations of BoNT / A1 WT HC (wild-type A1 botulinum toxin heavy chain, hereinafter referred to as A1 WT HC) and recombinant peptides were based on the molar concentration of BoNT / A (in this specification, BoNT / A is defined as including both wild-type and recombinant botulinum toxin serotypes. It will be obvious to those skilled in the art that BoNT / A in the embodiments of this application refers to wild-type BoNT / A unless otherwise stated) were applied at 5-fold intervals, from 5-fold to a maximum of 15625-fold. After treating with BoNT / A and HC, the culture medium was replaced with fresh medium, and after further culturing for 2 days, the cells were treated with lysis buffer and subjected to ELISA. In the ELISA assay, anti-SNAP25 was... 197After the antibody (Medytox) was coated onto an immunoplate, it reacted with cell lysate to capture BoNT / A-cleaved SNAP25 cells. Detection was then performed using biotinylated anti-SNAP25 antibody (LS Bio) and streptavidin-HRP (Thermo Scientific). The colorimetric reaction was performed using a chromogenic reagent (TMB substrate, Sigma-Aldrich), and absorbance was measured at 450 nm using a microplate reader (SpectraMax i3, Molecular Devices). Graphs and analyses were performed using Graphpad Prism 7.05 (GraphPad Software Inc., California, USA). For responses based on HC treatment concentrations, the half-maximal inhibitory concentration (IC50) was calculated using a four-parameter logistic (4PL) nonlinear regression method. 50 The IC50 (μM) value of the calculated variant HC was divided by the IC50 (μM) value of A1 WT HC, and the relative inhibitory activity values relative to the wild-type A1 botulinum toxin heavy chain are shown in the table below.
[0152]
[0153] Based on ELISA-based competitive analysis of the botulinum toxin heavy chain, the recombinant peptide according to one embodiment exhibited a high relative inhibitory activity value compared to the wild-type receptor-binding domain, thus confirming its enhanced receptor binding affinity. This demonstrates that, compared to the wild-type, the recombinant peptide of one embodiment can exhibit superior potency and improved safety.
[0154] Example 3: Preparation and purification of domain-substituted recombinant botulinum toxin After confirming the effectiveness of the receptor-binding domains of SEQ ID NO: 1 to 7, as demonstrated in Examples 1 and 2, recombinant receptor-binding domains further including additional amino acid substitutions in the sequences of SEQ ID NO: 1 to 7 were designed. For example, the recombinant botulinum toxin of SEQ ID NO: 8 includes a receptor-binding domain comprising all amino acid mutations of the recombinant polypeptide of SEQ ID NO: 7, and includes additional mutations. The additional mutations were selected at positions that are conserved common amino acids in type A2 and type A6 botulinum toxins, but different amino acids at the corresponding positions in type A1 botulinum toxin. At the corresponding positions, the amino acids in type A1 botulinum toxin were replaced with conserved amino acids in type A2 and type A6 botulinum toxins.
[0155] Then, recombinant botulinum toxin including the designed recombinant receptor-binding domain was prepared.
[0156] Specifically, using the pMTL80000 vector system, a recombinant full-length botulinum toxin gene, including both the light and heavy chains of recombinant botulinum toxin type A, was cloned via site-directed mutagenesis. The cloned preparations are shown in Table 2 below. For the recombinant botulinum toxin, a toxin gene-inactivated, non-toxic Hall A-hyper strain was prepared using the ClosTron system and then used.
[0157] Table 2
[0158] Non-toxic Clostridium botulinum strains (including strains with inactivated or knocked-out toxin genes) can be used in methods for preparing purified recombinant botulinum toxin or purified recombinant botulinum toxin complexes. Methods for preparing strains with inactivated or knocked-out toxin genes can be employed using methods conventionally used in the art. The recombinant botulinum toxins of SEQ ID NOs: 8 to 21 prepared by the ClosTron method were purified in a 150 kDa form without the complex components. Furthermore, the cell-penetrating peptide IMTP8 was further ligated to each of the recombinant botulinum toxins of SEQ ID NOs: 10 and 11 using a GS adapter, thereby further preparing two recombinant polypeptides (SEQ ID NOs 20 and 21, respectively). All preparations of the above-described recombinant botulinum toxins were carried out in facilities authorized by the regulatory authority to produce toxins.
[0159] Example 4: Evaluation of the thermal stability of recombinant botulinum toxin The thermal stability of the recombinant botulinum toxins SEQ ID NO: 10 and 11 prepared in Example 3 was compared. The midpoint temperature (Tm) of thermal denaturation was evaluated as a stability assessment method, with a higher midpoint temperature generally preferred. The thermal stability of each domain-substituted recombinant botulinum toxin type A was evaluated using protein thermal shift analysis (PTS). The PTS was performed using a Protein Thermal Shift Dye Kit (Catalog No.: 4461146, Applied Biosystems) according to the manufacturer's method. Specifically, 10 μg of each recombinant botulinum toxin was mixed with protein thermal shift dye and buffer to a final volume of 20 μL. The mixture was then heated to 95 °C at 20 °C every 60 seconds using a real-time quantitative polymerase chain reaction (RT-PCR) system (C1000 thermal cycler, equipped with a CFX96 optical reaction module, Bio-Rad). The ROX signal was detected simultaneously. The melting temperature (Tm) of each recombinant botulinum toxin was determined based on the melting curves. The melting temperatures of the recombinant botulinum toxins are shown below. Figure 1 And Table 3.
[0160] Table 3
[0161] The results showed that the recombinant botulinum toxins SEQ ID NO: 10, 11, SEQ ID NO: 12, 13, 14, 16, and 20 exhibited increased thermal stability compared to the wild type. Specifically, the melting temperature of wild-type A1 botulinum toxin was 52.8°C, while the melting temperatures of SEQ ID NO: 10 and SEQ ID NO: 11 increased to 54.2°C and 54.3°C, respectively. The melting temperature of wild-type A1 botulinum toxin was 52.7°C, while the melting temperatures of SEQ ID NO: 12, 13, 14, 16, and 20 increased to 55.5°C, 55.5°C, 54.5°C, 54.0°C, and 56.0°C, respectively. This confirms that the thermal stability of the recombinant botulinum toxins according to this application is significantly improved compared to the wild type.
[0162] Example 5: Evaluation of the efficacy of recombinant botulinum toxin in mice (1) Recombinant botulinum toxin of SEQ ID NO: 10 Materials and Methods Animals: Female CD1 (ICR) mice aged 5 to 6 weeks were purchased from Orientbio Inc. After a one-week acclimatization and quarantine period, mice aged 6 to 7 weeks were used in the experiment. Mice were fed sterilized laboratory animal solid feed (R40-10, SAFE, France) on an ad libitum basis, and their drinking water was sterilized by high-temperature and high-pressure autoclaving before being available for free consumption. During the acclimatization, quarantine, and experimental periods, mice were housed under the following specific pathogen-free conditions: temperature 23±3℃, relative humidity 55±15%, light duration 12 hours (8:00 AM to 8:00 PM), ventilation rate 15 times / hour, and illuminance 150 Lux to 300 Lux. This study was conducted after review and approval by the Animal Ethics Committee of Medytox Inc. (A-2022-007, A-2024-005).
[0163] Test substance: 100 units of Coretox (Lot No.: E623001, Medytox) were used for type A botulinum toxin product (BoNT / A). Recombinant botulinum toxin of SEQ ID NO: 10 was prepared to 163 U / mL and used in the experiment. The potency of the recombinant botulinum toxin was based on the efficacy value determined by a mouse potency assay prior to the potency test. In the potency test, all test substances were administered at the same dose based on units (U: representing the value of botulinum toxin biological activity; 1 U is the median lethal dose in mice determined by intraperitoneal administration).
[0164] The type A botulinum toxin product and the recombinant botulinum toxin in the examples were diluted to concentrations of 6 U / mL, 20 U / mL, and 60 U / mL, respectively, before application.
[0165] The date of administration of the test substance was designated as day 0. Mice were anesthetized with an injection of anesthetic (100 mg / kg ketamine hydrochloride + 10 mg / kg xylazine) and each test substance was administered to the right gastrocnemius muscle of mice at a dose of 0.2 mL / kg using a Hamilton syringe, according to Table 4 which shows the composition of each group.
[0166] Table 4
[0167] The DAS (Displacement of Muscles) assessment method, which visually evaluates the degree of muscle paralysis in mice, was used for evaluation. Table 5 (DAS Assessment Criteria for Mice) shows the DAS values as representing the degree of muscle paralysis based on the shape of the toe on the applied side in the mice.
[0168] Table 5
[0169] Based on the experimental group composition in Table 4, DAS was evaluated from day 1 post-administration at dosages of 1.2 U / kg, 4 U / kg, and 12 U / kg until the DAS score reached 0. The time to a DAS score of 0 was measured for each individual, and the mean DAS recovery time was calculated. Regarding body weight, to compare the impact on safety, for the high-dose group (12 U / kg), the change in body weight at week 1 post-administration relative to pre-administration was compared between the type A botulinum toxin product group and the recombinant botulinum toxin group. Statistical analysis: Graphs and DAS ED were performed using GraphPad Prism 7.05 (GraphPad Software Inc., California, USA). 50 The calculations were performed using SPSS 25.0 (SPSS Inc., Illinois, USA) and Excel (2013, Microsoft, USA). Normality was tested using the Kolmogorov-Smirnov test. Nonparametric data were analyzed using the Mann-Whitney test, and parametric data were analyzed using a two-tailed t-test. A p-value less than 0.05 was considered statistically significant. Results: See [link to results]. Figure 2 DAS scores were evaluated after a single administration of 1.2 U / kg, 4 U / kg, and 12 U / kg doses of botulinum toxin type A (BoNT / A: Coretox Inj.) and the recombinant botulinum toxin of this application to the right gastrocnemius muscle of mice. The results showed significantly higher DAS scores compared to BoNT / A in the 1.2 U / kg recombinant botulinum toxin group on days 3, 4, and 7 post-administration, and in the 4 U / kg recombinant botulinum toxin group on days 7, 14, and 21 post-administration. In the 1.2 U / kg, 4 U / kg, and 12 U / kg BoNT / A groups, recovery was observed in all individuals at weeks 2, 4, and 6 post-administration, respectively. In the same dose of recombinant botulinum toxin groups, recovery was further observed in all individuals at weeks 3, 5, and 8. Figure 2By calculating the DAS recovery time of each individual and comparing the duration of action, the results confirmed that the average duration of action for the BoNT / A administration groups (1.2 U / kg, 4 U / kg, and 12 U / kg) was 9.0 days, 19.8 days, and 33.8 days, respectively, while the average duration of action for the recombinant botulinum toxin administration groups (1.2 U / kg, 4 U / kg, and 12 U / kg) was 17.5 days, 29.2 days, and 42.8 days, respectively. The duration of action increased by 1.9 times, 1.5 times, and 1.3 times for each dose. In the 1.2 U / kg and 4 U / kg recombinant botulinum toxin administration groups, the duration of action was significantly longer than that for the BoNT / A administration group (Table 6). In the 12 U / kg administration group, the average change in body weight at week 1 post-administration relative to pre-administration was 97% in the BoNT / A administration group and 95% in the SEQ ID NO: 10 administration group; no significant difference was observed.
[0170] Table 6
[0171] p<0.01, †p=0.081, compared with the same dose of BoNT / A, two-tailed t-test or Mann-Whitney test. Based on the above results in mice, it was confirmed that the recombinant botulinum toxin of this application is more potent and has a longer duration of action compared to botulinum toxin type A products (BoNT / A).
[0172] (2) Recombinant botulinum toxin of SEQ ID NO: 11 Except for the preparation of the recombinant botulinum toxin of SEQ ID NO: 11 at 384 U / mL and its use in experiments, the efficacy was evaluated using the same methods as in the examples of the recombinant botulinum toxin of SEQ ID NO: 10.
[0173] Results: DAS evaluation was performed after single administration of 1.2 U / kg, 4 U / kg, and 12 U / kg doses of botulinum toxin type A and recombinant botulinum toxin SEQ ID NO: 11 to the right gastrocnemius muscle of mice. The results showed that the 1.2 U / kg and 4 U / kg SEQ ID NO: 11 administration groups exhibited increased DAS scores compared to BoNT / A. Figure 3 In the BoNT / A administration groups of 1.2 U / kg, 4 U / kg, and 12 U / kg, recovery was observed in all individuals at weeks 2, 4, and 6, respectively. In the same dose of recombinant botulinum toxin administration groups, recovery was observed in all individuals at further extended weeks 3, 5, and 7. Figure 3By calculating the DAS recovery time of each individual and comparing the duration of action, the results confirmed that the average duration of action for the BoNT / A administration groups (1.2 U / kg, 4 U / kg, and 12 U / kg) was 7.2 days, 16.7 days, and 31.5 days, respectively, and for the recombinant botulinum toxin administration groups (1.2 U / kg, 4 U / kg, and 12 U / kg) was 14.0 days, 25.3 days, and 36.2 days, respectively. The duration of action increased by 1.9 times, 1.5 times, and 1.1 times for each dosage. In the 1.2 U / kg recombinant botulinum toxin administration group, the duration of action was significantly longer than that of the BoNT / A administration group (Table 7). In the 12 U / kg administration group, the average change in body weight at week 1 post-administration relative to pre-administration was 99% in the BoNT / A administration group and 104% in the SEQ ID NO: 11 administration group; no weight loss was observed.
[0174] Table 7
[0175] p<0.05, †p=0.089, compared with the same dose of BoNT / A, two-tailed t-test or Mann-Whitney test. Based on the above results in mice, it was confirmed that the recombinant botulinum toxin of SEQ ID NO: 11 is more potent and has a longer duration of action compared to botulinum toxin type A (BoNT / A).
[0176] Example 6: Evaluation of the efficacy of recombinant botulinum toxin in rats Materials and Methods Animals: Six-week-old female Sprague-Dawley SD rats were purchased from Orientbio Inc. After a one-week acclimatization and quarantine period, seven-week-old rats were used in the experiment. The housing environment was the same as in Example 5. This study was conducted after review and approval (A-2023-001) by the Animal Ethics Committee of Medytox Inc.
[0177] Test substance: 100 units of Coretox (lot number: E623001, Medytox) were used for the type A botulinum toxin product (BoNT / A). Recombinant botulinum toxin SEQ ID NO: 10 was prepared at 444 U / mL, and recombinant botulinum toxin SEQ ID NO: 11 was prepared at 366 U / mL and used in the experiment. For the placebo (placebo administration group), only the botulinum toxin in the recombinant botulinum toxin was removed; the remaining excipient components were used in the same manner.
[0178] Before application, the botulinum toxin type A product and recombinant botulinum toxin were diluted at 120 U / mL respectively.
[0179] The date of administration of the test substance was designated as day 0. Mice were anesthetized with an injection of an anesthetic (60 mg / kg ketamine hydrochloride + 10 mg / kg xylazine) and each test substance was administered to the right gastrocnemius muscle of rats at a dose of 0.1 mL / kg using a Hamilton syringe, according to Table 8 which shows the composition of each group.
[0180] Table 8
[0181] The evaluation employed the visual assessment method of DAS (digit abduction score) to evaluate the degree of muscle paralysis in rats, and the compound muscle action potential (CMAP) test. CMAP measures the action potential of muscles in response to external electrical stimulation. Table 9 (Rats DAS Evaluation Criteria) shows that the DAS values represent the degree of muscle paralysis based on the shape of the toe on the applied side in rats, and the CMAP values represent the degree of direct muscle contraction inhibition caused by nerve blockade.
[0182] Table 9
[0183] CMAP was measured in the gastrocnemius muscle region on the left side (untreated site) of each rat using an UltraPro S100 device. After anesthesia with an injectable anesthetic, the hair at the measurement site was shaved, and the rats were placed in a prone position. The cathode was positioned at the sciatic nerve site on the side of the leg to be tested, and the anode was positioned approximately 0.5 cm from the site relative to the spine. The recording electrode and reference electrode were positioned at the gastrocnemius and Achilles tendon sites, respectively, and the ground electrode was positioned at the rectus femoris site. The stimulation intensity and duration were set to 25 mA to 30 mA and 0.2 ms, respectively, and the amplifier filter range was set to 60 Hz to 2–10 K. Under these conditions, the height of the waveform from baseline to peak value was quantified as the CMAP measurement. DAS measurements were performed from day 3 until the DAS score reached 0, according to the experimental group composition in Table 8. The time to a DAS score of 0 was measured for each individual, and the mean DAS recovery time was calculated. To evaluate diffusion to untreated sites, CMAP was measured in the left gastrocnemius muscle on day 7 post-treatment. Furthermore, to compare CMAP... AAC (CMAP) baselineAUC - CMAP AUC CMAP was measured at 2-3 week intervals until a recovery in CMAP values was observed, and calculations were performed based on a reported literature (Dermatologic Surgery 2020; 46(12): e132). Statistical analysis: Same as in Example 1. Results: DAS evaluation was performed after a single administration of 12 U / kg of type A botulinum toxin and recombinant botulinum toxin to the right gastrocnemius muscle of rats. The results showed that in the 12 U / kg SEQ ID NO: 10 recombinant botulinum toxin administration group, significantly increased DAS scores compared to BoNT / A were observed on days 49 and 56 post-administration. Figure 4 An increased DAS score compared to BoNT / A was also observed in the recombinant botulinum toxin administration group (SEQ ID NO: 11). Figure 4 In the BoNT / A administration group, all individuals recovered at week 10 post-administration; in the same dose of SEQ ID NO: 10 recombinant botulinum toxin administration group, all individuals recovered at a further extended week 14; and in the SEQ ID NO: 11 botulinum toxin administration group, all individuals recovered at week 11. Figure 4 By calculating the DAS recovery time of each individual and comparing the duration of action, the results confirmed that the average duration of action was 50.2 days in the BoNT / A administration group, 72.3 days in the recombinant botulinum toxin administration group (SEQ ID NO: 10), and 65.3 days in the recombinant botulinum toxin administration group (SEQ ID NO: 11), with the duration of action significantly increased by 1.4 times and 1.3 times, respectively (Table 10).
[0184] Table 10
[0185] p<0.05, compared with the BoNT / A treatment group, two-tailed t-test. On day 7 after botulinum toxin administration, CMAP was measured in the gastrocnemius muscle of the contralateral treatment site. The results showed no significant difference between the recombinant botulinum toxin treatment group (SEQ ID NO: 10) and the BoNT / A treatment group, while a significantly increased CMAP value was observed in the recombinant botulinum toxin treatment group (SEQ ID NO: 11). Figure 4 Calculate CMAP AAC Comparative studies showed that the average value in the BoNT / A group was 3558.5, the average value in the SEQ ID NO: 10 botulinum toxin group was 3883.3, a significant increase of 1.1 times that of the BoNT / A group, and the average value in the SEQ ID NO: 11 botulinum toxin group was 3592.5, with equal or greater values observed. In the 12 U / kg application groups, regarding the change in body weight at week 1 post-application relative to pre-application levels, the average value in the type A botulinum toxin group was 107%, the average value in the SEQ ID NO: 10 botulinum toxin group was 108%, and the average value in the SEQ ID NO: 11 botulinum toxin group was 108%, showing an effect comparable to that of the BoNT / A group.
[0186] Based on the above results in rats, it was confirmed that recombinant botulinum toxin is more potent and has a longer duration of action than botulinum toxin type A (BoNT / A), and the diffusion of recombinant botulinum toxin SEQ ID NO: 11 was reduced compared to the BoNT / A administration group.
[0187] Example 7: DAS ED of recombinant botulinum toxin in mice 50 IM LD 50 test Materials and Methods The animals and their housing conditions were the same as in Example 5, and this study was conducted after review and approval by the Animal Ethics Committee of Medytox Inc. (A-2022-007, A-2022-008).
[0188] Test substance: 100 units of Coretox (lot number: E623001, Medytox) were used in the type A botulinum toxin product (BoNT / A). Recombinant botulinum toxin SEQ ID NO: 10 was prepared at 1306 U / mL, and recombinant botulinum toxin SEQ ID NO: 11 was prepared at 1056 U / mL and used in the experiment. For the placebo (placebo administration group), only the botulinum toxin in the recombinant botulinum toxin was removed; the remaining excipient components were used in the same manner.
[0189] For type A botulinum toxin products and recombinant botulinum toxin, in DAS ED 50 Before application, the solution was diluted to concentrations of 6 U / mL, 20 U / mL, 60 U / mL, and 200 U / mL, respectively, and then diluted in 1M LD. 50 Before application, the sample was diluted to concentrations of 300 U / mL, 450 U / mL, and 675 U / mL, respectively. The experiment was repeated twice.
[0190] Day 0 was designated as the date of administration of the test substance. Mice were anesthetized with an injection of anesthetic (100 mg / kg ketamine hydrochloride + 10 mg / kg xylazine) and administered according to the group composition (DAS ED in Table 11). 50 Experimental group, IM LD in Table 12 50 In the experimental group, each test substance was administered to the right gastrocnemius muscle of mice at a dose of 0.2 mL / kg using a Hamilton syringe.
[0191] Table 11
[0192] Table 12
[0193] The DAS (Displacement of Infantile Muscles) assessment method, which visually evaluates the degree of muscle paralysis in mice, was used for evaluation. The DAS values shown in Table 11 represent the degree of muscle paralysis based on the shape of the toes on the treated side in mice. According to the experimental group composition in Table 11, DAS measurements were performed from day 1 to day 14 after administration at dosages of 1.2 U / kg, 4 U / kg, 12 U / kg, and 40 U / kg. According to the experimental group composition in Table 12, the occurrence of mortality was confirmed for 14 consecutive days after administration at each dosage.
[0194] Statistics: For the highest DAS scores of each individual in the DAS trial, after fixing the values of the lowest 0 and highest 4 points using Graphpad Prism, the DAS ED was calculated using a three-parameter logistic model. 50 For each administered dose, the IMLD was calculated using SPSS software (SPSS Inc., Illinois, USA) through probit analysis. 50 value.
[0195] Results: DAS ED was calculated after a single administration of various doses of botulinum toxin type A product and recombinant botulinum toxin from the examples to the right gastrocnemius muscle of mice. 50 The results, based on the average of the two replicates, showed that the BoNT / A administration group had a dose of 1.7 U / kg, the recombinant botulinum toxin administration group (SEQ ID NO: 10) had a dose of 1.2 U / kg, and the recombinant botulinum toxin administration group (SEQ ID NO: 11) had a dose of 1.9 U / kg. The recombinant botulinum toxin administration group (SEQ ID NO: 10) showed an increase of approximately 1.4 times that of the BoNT / A administration group (Table 13). As shown in Table 12, after administration of type A botulinum toxin products and the recombinant botulinum toxin of the examples to the right gastrocnemius muscle of mice, the median lethal dose (MDL) was calculated based on the occurrence of deaths in individuals 14 consecutive days after administration. 50 The results showed that the average dose in the two trials of the BoNT / A group was 61.7 U / kg, the dose in the recombinant botulinum toxin group of SEQ ID NO: 10 was 78.0 U / kg, and the dose in the recombinant botulinum toxin group of SEQ ID NO: 11 was 97.1 U / kg. Compared with the BoNT / A group, the dose in the recombinant botulinum toxin group of SEQ ID NO: 10 increased by about 1.3 times, and the dose in the recombinant botulinum toxin group of SEQ ID NO: 11 increased by about 1.6 times (Table 13).
[0196] Table 13
[0197] Safety margin: IM LD50 (U / kg) / DAS ED 50 (U / kg) By DAS ED 50 and IM LD 50 The safety margins were calculated as follows: 36.3 for the BoNT / A group, 65.0 for the recombinant botulinum toxin group (SEQ ID NO: 10), and 51.1 for the recombinant botulinum toxin group (SEQ ID NO: 11). Compared to the BoNT / A group, the safety margins increased 1.8-fold for the recombinant botulinum toxin group (SEQ ID NO: 10) and 1.4-fold for the recombinant botulinum toxin group (SEQ ID NO: 11). These results confirm that recombinant botulinum toxin is more potent and has improved safety.
[0198] Example 8: Evaluation of the efficacy of recombinant botulinum toxin in mice (1) Recombinant botulinum toxins of SEQ ID NO: 22 and 23 Recombinant botulinum toxin of SEQ ID NO: 22 was prepared at 416 U / mL, and recombinant botulinum toxin of SEQ ID NO: 23 was prepared at 424 U / mL. Experiments were conducted, and the composition of the test groups is shown in Table 14 below. The test substances or assay methods used for efficacy evaluation were the same as those used in the recombinant botulinum toxin example of SEQ ID NO: 10 above. Regarding CMAP determination, CMAP was calculated using the same method as in Example 6. AAC value.
[0199] Table 14
[0200] DAS scores were evaluated after single administration of 1.2 U / kg, 4 U / kg, and 12 U / kg doses of botulinum toxin type A and SEQ ID NO: 22 to the right gastrocnemius muscle of mice. Results showed that in the 1.2 U / kg SEQ ID NO: 22 botulinum toxin administration group, significantly increased DAS scores compared to BoNT / A were observed on days 1, 3, 4, and 7 post-administration. For the SEQ ID NO: 23 botulinum toxin administration group, increased DAS scores compared to BoNT / A were observed in the 1.2 U / kg and 4 U / kg administration groups. Figure 5By calculating the DAS recovery time of each individual and comparing the duration of action, the results confirmed that the average duration of action for the 1.2 U / kg, 4 U / kg, and 12 U / kg BoNT / A administration groups was 9.8 days, 21.0 days, and 25.3 days, respectively, while the average duration of action for the SEQ ID NO: 22 botulinum toxin administration group was 15.2 days, 23.0 days, and 37.4 days, respectively. That is, compared with wild-type BoNT / A, the duration of action of the recombinant peptide of this application was observed to increase by 1.6 times, 1.1 times, and 1.5 times at each dose, respectively. The average DAS recovery time for the SEQ ID NO: 23 botulinum toxin administration group was 16.3 days, 27.3 days, and 35.5 days, respectively, with the duration of action increasing by 1.7 times, 1.3 times, and 1.4 times at each dose (Table 15). Furthermore, in the 12 U / kg botulinum toxin administration groups of SEQ ID NO: 22 and SEQ ID NO: 23, the duration of action was significantly longer than that of the BoNT / A administration group (Table 15). Regarding DAS ED 50 In terms of calculation results, the BoNT / A group had a potency of 3.2 U / kg, the SEQ ID NO: 22 group had a potency of 1.1 U / kg, and the SEQ ID NO: 23 group had a potency of 2.1 U / kg, indicating a potency 2.9 times and 1.5 times greater than the BoNT / A group, respectively. CMAP measurements were performed on day 7 post-application. The results showed that in the SEQ ID NO: 22 and SEQ ID NO: 23 botulinum toxin application groups, the CMAP values at the application site were significantly lower than those in the BoNT / A group, confirming its stronger potency. No significant difference was observed in the CMAP values at the contralateral application site compared to the BoNT / A group. Figure 6 Calculate CMAP AAC Comparative studies showed that the average efficacy of the BoNT / A group was 2077.1, the average efficacy of the SEQ ID NO: 22 botulinum toxin group was 2680.3, and the average efficacy of the SEQ ID NO: 23 botulinum toxin group was 2612.9, all significantly increased to 1.3 times that of the BoNT / A group. In the 12 U / kg administration groups, regarding the change in body weight at week 1 post-administration relative to pre-administration, the average efficacy of the BoNT / A group was 96%, the average efficacy of the SEQ ID NO: 22 botulinum toxin group was 96%, and the average efficacy of the SEQ ID NO: 23 botulinum toxin group was 97%, observing efficacy levels comparable to the BoNT / A group. Based on these results in mice, it was confirmed that the botulinum toxins of SEQ ID NO: 22 and SEQ ID NO: 23, as recombinant peptides, are more potent and have a longer duration of action compared to botulinum toxin type A products (BoNT / A).
[0201] Table 15
[0202] p <0.05, a p =0.05, b p =0.08, compared with the same dose of BoNT / A, two-tailed t-test or Mann-Whitney test. (2) Recombinant botulinum toxins of SEQ ID NO: 14 and 15 The type A botulinum toxin product (BoNT / A) was the same as in Example 1. Recombinant botulinum toxin SEQ ID NO: 14 was prepared at 394 U / mL, and recombinant botulinum toxin SEQ ID NO: 15 was prepared at 419 U / mL, and both were used in the experiment. The composition of the experimental group is shown in Table 16, and all other contents are the same as those described in Example 8 (1) above. However, CMAP was not calculated. AAC .
[0203] Table 16
[0204] DAS (Diagnosis and Assay) scores were evaluated after a single administration of 1.2 U / kg, 4 U / kg, and 12 U / kg doses of type A botulinum toxin and recombinant botulinum toxin to the right gastrocnemius muscle of mice. The results showed that in the 4 U / kg SEQ ID NO: 14 botulinum toxin administration group, an increased DAS score compared to BoNT / A was observed. Figure 7 The duration of action was compared by calculating the DAS recovery time of each individual. Results showed that the duration of action in the recombinant botulinum toxin administration group was equal to or further increased than that of BoNT / A (Table 17). Regarding the DAS ED50 calculations, the BoNT / A administration group was 5.8 U / kg, the SEQ ID NO: 14 administration group was 3.3 U / kg, and the SEQ ID NO: 15 administration group was 3.0 U / kg, indicating a potency 1.8 times and 1.9 times greater than that of the BoNT / A administration group, respectively. CMAP measurements were performed on day 7 post-administration. Results showed that in the SEQ ID NO: 14 and SEQ ID NO: 15 botulinum toxin administration groups, the CMAP values at the application site were significantly lower than those in the BoNT / A administration group, confirming its stronger potency. Furthermore, in the SEQ ID NO: 15 botulinum toxin administration group, the CMAP values at the non-application site were significantly higher than those in the BoNT / A administration group, confirming its diffusion inhibition effect. Figure 8In the 12 U / kg administration groups, regarding the change in body weight at week 1 post-administration relative to pre-administration, the BoNT / A administration group averaged 95%, and the SEQ ID NO: 14 administration group averaged 97%, with no significant difference observed between the two groups. However, the SEQ ID NO: 15 administration group averaged 111%, showing a significant increase in body weight compared to the BoNT / A administration group (p<0.001). Based on these results in mice, it is confirmed that the recombinant botulinum toxin of this application is more potent and has a longer duration of action than botulinum toxin type A (BoNT / A), and exhibits improved diffusion.
[0205] Table 17
[0206] (3) Recombinant botulinum toxins of SEQ ID NO: 12 and 13 Recombinant botulinum toxin of SEQ ID NO: 12 was prepared at 559 U / mL, and recombinant botulinum toxin of SEQ ID NO: 13 was prepared at 440 U / mL. The composition of the test groups is shown in Table 18 below. The test substances or assay methods used for efficacy evaluation are the same as those used in the recombinant botulinum toxin examples of SEQ ID NO: 22 and 23 above.
[0207] Table 18
[0208] DAS evaluation was performed after a single administration of 1.2 U / kg, 4 U / kg, and 12 U / kg doses of botulinum toxin type A, as well as botulinum toxins SEQ ID NO: 12 and 13, to the right gastrocnemius muscle of mice. The results showed increased DAS scores compared to BoNT / A in the 1.2 U / kg and 4 U / kg groups, indicating equal or superior efficacy, and equal efficacy was observed in the 12 U / kg group. Figure 9 By calculating the DAS recovery time of each individual and comparing the duration of action, the results showed that the duration of action was significantly longer in the 1.2 U / kg SEQ ID NO: 12 botulinum toxin administration group and the 4 U / kg SEQ ID NO: 13 botulinum toxin administration group compared to the BoNT / A administration group (Table 19). Regarding DAS ED 50In terms of calculation results, the BoNT / A group (3.0 U / kg), the SEQ ID NO: 12 botulinum toxin group (2.5 U / kg), and the SEQ ID NO: 13 botulinum toxin group (2.8 U / kg) showed 1.2 times and 1.1 times the potency of the BoNT / A group, respectively. CMAP measurements were performed on day 7 post-application. Equal levels of effect were observed at the application site CMAP values. However, a significant increase in CMAP values was observed in the SEQ ID NO: 12 group at the contralateral application site. Figure 10 Calculate CMAP AAC Comparative studies showed that the average efficacy in the BoNT / A group was 2502.2, while the average efficacy in the SEQ ID NO: 13 botulinum toxin group was 3041.9, significantly increasing to 1.2 times that of the BoNT / A group. In the 12 U / kg administration groups, regarding the change in body weight at week 1 post-administration relative to pre-administration, the BoNT / A group averaged 96%, the SEQ ID NO: 12 botulinum toxin group averaged 95%, and the SEQ ID NO: 13 botulinum toxin group averaged 97%, observing efficacy levels comparable to the BoNT / A group. Based on these results in mice, it was confirmed that compared to botulinum toxin type A (BoNT / A), the recombinant botulinum toxins SEQ ID NO: 12 and 13 are more potent, have a longer duration of action, and exhibit improved diffusion.
[0209] Table 19
[0210] p<0.05, p<0.01, compared with the same dose of BoNT / A administration group, two-tailed t-test (4) Recombinant botulinum toxin of SEQ ID NO: 16 The recombinant botulinum toxin of SEQ ID NO: 16 was prepared at 444 U / mL, and the composition of the test group is shown in Table 20 below. The test substances or assay methods used for efficacy evaluation are the same as those used in the recombinant botulinum toxin examples of SEQ ID NO: 22 and 23 above.
[0211] Table 20
[0212] DAS scores were evaluated after single administration of 1.2 U / kg, 4 U / kg, and 12 U / kg doses of botulinum toxin type A and recombinant botulinum toxin SEQ ID NO: 16 to the right gastrocnemius muscle of mice. Results showed that in the 12 U / kg SEQ ID NO: 16 recombinant botulinum toxin administration group, a significantly higher DAS score than BoNT / A was observed on day 21 post-administration, and this increase was also observed at other time points. Figure 11 The duration of action was compared by calculating the DAS recovery time of each individual. Results showed that the duration of action was significantly longer in the 4 U / kg SEQ ID NO: 16 recombinant botulinum toxin administration group compared to the BoNT / A administration group (Table 21). Regarding DAS ED 50 In terms of calculation results, the BoNT / A group had a potency of 2.0 U / kg, while the recombinant botulinum toxin group (SEQ ID NO: 16) had a potency of 1.8 U / kg, indicating a 1.1-fold increase in potency compared to the BoNT / A group. CMAP measurements were performed on day 7 post-administration. The results showed that the CMAP value at the application site was significantly lower in the recombinant botulinum toxin group (SEQ ID NO: 16) compared to the BoNT / A group, confirming its stronger potency. No significant difference was observed in the CMAP value at the contralateral application site compared to the BoNT / A group. Figure 12 Calculate CMAP AAC The results showed that the average efficacy in the BoNT / A group was 2061.9, while the average efficacy in the SEQ ID NO: 16 botulinum toxin group was 2659.7, significantly increasing to 1.3 times that of the BoNT / A group. In the 12 U / kg administration groups, regarding the change in body weight at week 1 post-administration relative to pre-administration, the average was 94% in the BoNT / A group and 93% in the SEQ ID NO: 16 recombinant botulinum toxin group, with no significant difference observed between the two groups. Based on these results in mice, it was confirmed that the recombinant botulinum toxin of SEQ ID NO: 16, compared to botulinum toxin type A (BoNT / A), is more potent and has a longer duration of action.
[0213] Table 21
[0214] p <0.05, a p =0.05, compared with the same dose of BoNT / A, two-tailed t-test or Mann-Whitney test. Example 9: Evaluation of the efficacy of recombinant botulinum toxins SEQ ID NO: 24 to 32 and 43 in mice The efficacy was evaluated under the same conditions as in Example 5, including the animals and their rearing environment.
[0215] Test substance: 100 units of Coretox (lot number: E623001, Medytox) were used for type A botulinum toxin product (BoNT / A). Recombinant botulinum toxin was prepared as a liquid and used in the experiment, diluted to concentrations of 6 U / mL, 20 U / mL, and 60 U / mL before administration. Ten recombinant botulinum toxins were used in the experiment, and a total of four experiments were conducted. The duration of action was compared by DAS evaluation after administration of type A botulinum toxin product and recombinant botulinum toxin at doses of 1.2 U / kg, 4 U / kg, and 12 U / kg to the right gastrocnemius muscle of mice, and body weight was compared at week 1 after administration at the 12 U / kg dose.
[0216] Results: DAS evaluation was performed after single administration of 1.2 U / kg, 4 U / kg, and 12 U / kg doses of botulinum toxin type A (BoNT / A: Coretox Inj.) and 10 recombinant botulinum toxins to the right gastrocnemius muscle of mice. The results showed that, for the recombinant botulinum toxin of SEQ ID NO: 24, the DAS duration at doses of 1.2 U / kg and 4 U / kg increased to 1.6 times and 1.1 times that of BoNT / A, respectively, and the duration of action at the 12 U / kg dose was at the same level. Regarding the recombinant botulinum toxin of SEQ ID NO: 25, the DAS duration at doses of 1.2 U / kg, 4 U / kg, and 12 U / kg was observed to increase to 1.3 times, 1.4 times, and 1.2 times that of BoNT / A, respectively; regarding the recombinant botulinum toxin of SEQ ID NO: 26, the DAS duration at doses of 1.2 U / kg, 4 U / kg, and 12 U / kg was observed to increase to 1.2 times, 1.1 times, and 1.3 times that of BoNT / A, respectively; and regarding the recombinant botulinum toxin of SEQ ID NO: 27, the DAS duration at doses of 1.2 U / kg, 4 U / kg, and 12 U / kg was observed to increase to 1.2 times, 1.1 times, and 1.1 times that of BoNT / A, respectively. Regarding the recombinant botulinum toxin of SEQ ID NO: 28, the DAS duration at doses of 1.2 U / kg and 4 U / kg was observed to be 1.2 times and 1.3 times that of BoNT / A, respectively, and the DAS duration at a dose of 12 U / kg was at the same level as BoNT / A. Regarding the recombinant botulinum toxins of SEQ ID NO: 29 to 31, the DAS duration at doses of 1.2 U / kg, 4 U / kg, and 12 U / kg was observed to be at the same level as BoNT / A. Regarding the recombinant botulinum toxin of SEQ ID NO: 32, the DAS duration at doses of 1.2 U / kg and 4 U / kg was observed to be 1.6 times and 1.3 times that of BoNT / A, respectively, and the DAS duration at a dose of 12 U / kg was at the same level as BoNT / A. With regard to SEQ ID NO: 43, it was observed that the duration of action of DAS at a dose of 1.2 U / kg increased to 1.4 times that of BoNT / A, and the duration of action at doses of 4 U / kg and 12 U / kg was at the same level as that of BoNT / A.
[0217] Furthermore, after administration of recombinant botulinum toxin at doses of 1.2 U / kg, 4 U / kg, and 12 U / kg of SEQ ID NO: 28 to 32 and 43, safety was evaluated by observing changes in body weight. The results showed that the weight reduction was at the same level as that of wild-type BoNT / A, thus confirming that it exhibits a safety profile at least equivalent to that of wild-type botulinum toxin.
[0218] Based on the above results in mice, it was confirmed that recombinant botulinum toxin has an increased duration of action or equal or higher safety compared to wild-type botulinum toxin product A (BoNT / A).
[0219] Example 10: Evaluation of the efficacy of recombinant botulinum toxins SEQ ID NO: 18 and 19 in mice The efficacy was evaluated under the same conditions as in Example 5, including the animals and their rearing environment.
[0220] Test substance: 100 units of Coretox (lot number: E623001, Medytox) were used for type A botulinum toxin product (BoNT / A). Recombinant botulinum toxin was prepared as a liquid and used in the experiment, diluted to a concentration of 60 U / mL before administration. Two recombinant botulinum toxins were used in the experiment, and two trials were conducted. Efficacy was compared by CMAP evaluation after administration of a 12 U / kg dose of type A botulinum toxin product and recombinant botulinum toxin to the right gastrocnemius muscle of mice, and body weight was compared at week 1 post-administration.
[0221] Results: Following a single administration of 12 U / kg of botulinum toxin type A (BoNT / A: Coretox Inj.) and recombinant botulinum toxin of SEQ ID NO: 18 to the right gastrocnemius muscle of mice, CMAP values at the application site were compared at week 1. The mean CMAP in the SEQ ID NO: 18 group was 0.1 mV, significantly lower than the mean CMAP of 0.9 mV in the BoNT / A group (p<0.001). Regarding the change in body weight at week 1, the change was 97% in the BoNT / A group and 93% in the SEQ ID NO: 18 group, with no significant difference observed. Following a single administration of 12 U / kg of recombinant botulinum toxin of SEQ ID NO: 19, CMAP values at the application site were compared at week 1. The mean CMAP in the SEQ ID NO: 19 group was 0.3 mV, significantly lower than the mean CMAP of 1.3 mV in the BoNT / A group (p<0.01). Regarding weight change in week 1, both the BoNT / A group and the botulinum toxin group (SEQ ID NO: 19) showed a 93% change in weight, indicating equivalent efficacy. Based on these results in mice, it was confirmed that the recombinant botulinum toxins (SEQ ID NO: 18 and 19) are more potent and have equivalent safety profiles compared to botulinum toxin type A (BoNT / A).
[0222] Example 11: Recombinant botulinum toxin of SEQ ID NO: 44 based on cell activity Materials and Methods The cell lines used in the experiment were the same as in Example 2. BoNT / A (150 kDa, Medytox, batch number: RBTS2301) and recombinant botulinum toxin SEQ ID NO: 44 (150 kDa, Medytox) were serially diluted at 300 U / well, 60 U / well, 12 U / well, 2.4 U / well, and 0.48 U / well, and treated for 48 hours. Subsequently, the cells were cultured for another 48 hours after changing the cell culture medium, treated with lysis buffer, and subjected to an ELISA assay. The ELISA assay was performed in the same manner as in Example 2.
[0223] result The cell-based activity of wild-type botulinum toxin and recombinant botulinum toxin was analyzed by ELISA. The results showed that the activity of the recombinant botulinum toxin treatment group increased to 11 times that of wild-type botulinum toxin.
[0224] Table 22
[0225] This confirms that recombinant peptides can exhibit superior efficacy compared to wild-type peptides.
[0226] A recombinant polypeptide according to one embodiment exhibits superior potency compared to a wild-type receptor-binding domain, said recombinant polypeptide comprising a receptor-binding domain having an amino acid mutation. Botulinum toxins comprising the recombinant polypeptide according to one embodiment exhibit greater potency, higher safety, or a longer half-life than wild-type botulinum toxins.
Claims
1. A recombinant polypeptide comprising: The receptor-binding domain of type A1 botulinum toxin The receptor-binding domain includes an amino acid mutation at at least one position, wherein the position is a conserved common amino acid in type A2 botulinum toxin and type A6 botulinum toxin, and a different amino acid at the corresponding position in type A1 botulinum toxin.
2. The recombinant polypeptide according to claim 1, wherein, The location of the amino acid mutation includes at least one selected from the group consisting of N880, W1068, and N1090.
3. The recombinant polypeptide according to claim 1, wherein, The receptor-binding domain includes at least one amino acid mutation selected from the group consisting of N880S, W1068M, and N1090S.
4. The recombinant polypeptide according to claim 2, wherein, The receptor-binding domain also includes an amino acid mutation at at least one position selected from the group consisting of N954, M968, T990, Q991, N1025, N1026, N1052, T1063, H1064, Y1117, T1232, and L1278.
5. The recombinant polypeptide according to claim 4, wherein, The receptor-binding domain further includes at least one amino acid mutation selected from the group consisting of N954S, M968I, T990N, Q991K, N1025T, N1026K, N1052K, T1063P, H1064R, Y1117F, T1232R, and L1278F.
6. The recombinant polypeptide according to claim 1, further comprising: Translocation domain The translocation domain includes polypeptides selected from the group consisting of translocation domains of type A1 botulinum toxin, type A2 botulinum toxin, type A6 botulinum toxin, and their variants.
7. The recombinant polypeptide according to claim 6, comprising: Translocation domains of type A1 botulinum toxin Wherein, the translocation domain includes an amino acid mutation at at least one position, wherein the position is a conserved common amino acid in type A2 botulinum toxin and type A6 botulinum toxin, while the corresponding position in type A1 botulinum toxin contains a different amino acid, or, It includes the translocation domain of type A1 botulinum toxin and includes a mutation at amino acid position 589.
8. The recombinant polypeptide according to claim 6, comprising: Translocation domains of type A1 botulinum toxin The amino acid mutation position of the translocation domain includes at least one selected from the group consisting of D589, L681, D696, I713, K730, E734, K779, N789, G804, E809, L815, K816 and A818.
9. The recombinant polypeptide according to claim 1, further comprising: Light chain domain, The light chain domain includes polypeptides selected from the group consisting of botulinum toxin type A1, botulinum toxin type A4, and their variants.
10. The recombinant polypeptide according to claim 9, wherein, The light chain structural domain includes: The first and second domains of the A1 type botulinum toxin light chain; or variants thereof, and the third and fourth domains of the A4 type botulinum toxin light chain; or variants thereof; or The first and second domains of the A1 type botulinum toxin light chain; or variants thereof, and the third and fourth domains of the A4 type botulinum toxin light chain; or variants thereof, wherein the leucine at position 260 in the light chain domains is replaced by phenylalanine, and the isoleucine at position 264 is replaced by arginine.
11. The recombinant polypeptide according to claim 1, wherein, The half-maximum inhibitory concentration (MCIC) value of the receptor-binding domain, obtained from the botulinum toxin heavy chain competitive analysis, is less than the MIC value of the wild-type receptor-binding domain.
12. The recombinant polypeptide according to claim 1, further comprising: Light chain domains and translocation domains Furthermore, compared to wild-type botulinum toxin type A, the recombinant polypeptide has stronger potency, higher safety, or a longer half-life.
13. The recombinant polypeptide according to claim 12, wherein, The recombinant polypeptide includes at least one of the recombinant botulinum toxins selected from SEQ ID NO: 8 to SEQ ID NO: 32, SEQ ID NO: 43, and SEQ ID NO:
44.
14. A recombinant polypeptide comprising: The receptor-binding domain of type A1 botulinum toxin The receptor-binding domain includes amino acid mutations at two or more positions selected from N954, Y1117, T1232, R1273, and L1278.
15. The recombinant polypeptide according to claim 14, wherein, The receptor-binding domain includes two or more amino acid mutations selected from N954S, Y1117F, T1232R, R1273K, and L1278F.
16. The recombinant polypeptide according to claim 14, wherein, The receptor-binding domain includes amino acid mutations at two or more positions selected from N954S, T1232R, and L1278F.
17. The recombinant polypeptide according to claim 14, wherein, Amino acid mutations in the receptor-binding domain include N954S and T1232R; N954S and L1278F; T1232R and L1278F; T1232R and R1273K; R1273K and L1278F; N954S, T1232R, and L1278F; Y1117F, R1273K, and L1278F; or T1232R, R1273K, and L1278F.
18. A recombinant polypeptide comprising: A variant of the receptor-binding domain of type A1 botulinum toxin. The half-maximum inhibitory concentration (MCIC) value of the receptor-binding domain variant, obtained from the botulinum toxin heavy chain competitive analysis, is lower than that of the wild-type receptor-binding domain.
19. The recombinant polypeptide according to claim 18, wherein, The variant of the receptor-binding domain includes an amino acid mutation at at least one position selected from the group consisting of N880, N954, M968, T990, Q991, N1025, N1026, N1052, T1063, H1064, W1068, N1090, Y1117, S1142, T1232, and L1278.
20. A recombinant botulinum toxin, comprising: A variant of botulinum toxin type A1 with a mutation in at least one amino acid in the receptor-binding domain sequence. The amino acid mutation includes at least one selected from the group consisting of N880S, N954S, M968I, T990N, Q991K, N1025T, N1026K, N1052K, T1063P, H1064R, W1068M, N1090S, Y1117F, S1142Y, S1142R, S1142I, S1142F, S1142H, T1232R, and L1278F, which, when administered to a subject requiring treatment, has at least one of potency and safety superior to wild-type A1 botulinum toxin, and the remaining items are at least equal to wild-type toxin.
21. The recombinant botulinum toxin according to claim 20, comprising: The light chain domain is selected from the group consisting of the A1 type botulinum toxin light chain, the A4 type botulinum toxin light chain, and their variants.
22. The recombinant botulinum toxin according to claim 21, wherein, The light chain structural domain includes: The first and second domains of the A1 type botulinum toxin light chain; or variants thereof, and the third and fourth domains of the A4 type botulinum toxin light chain; or variants thereof; or The first and second domains of the A1 type botulinum toxin light chain; or variants thereof, and the third and fourth domains of the A4 type botulinum toxin light chain; or variants thereof, wherein the leucine at position 260 in the light chain domains is replaced by phenylalanine, and the isoleucine at position 264 is replaced by arginine.
23. The recombinant botulinum toxin according to claim 20, comprising: Translocation domain Wherein, the translocation domain includes an amino acid mutation at at least one position, wherein the position is a conserved common amino acid in type A2 and type A6 botulinum toxin, but a different amino acid at the corresponding position in type A1 botulinum toxin; or, The translocation domain includes the translocation domain of type A1 botulinum toxin and includes at least one amino acid mutation selected from the group consisting of D589, E734 and E809.
24. A recombinant botulinum toxin, comprising: Variants of the light chain of botulinum toxin type A; and a receptor-binding domain comprising at least one amino acid mutation selected from the group consisting of N880S, N954S, M968I, T990N, Q991K, N1025T, N1026K, N1052K, T1063P, H1064R, W1068M, N1090S, S1142Y, S1142R, S1142I, S1142F, S1142H, Y1117F, T1232R, and L1278F.
25. The recombinant botulinum toxin according to claim 24, wherein, The receptor-binding domain includes recombinant peptides of SEQ ID NO: 1 to SEQ ID NO: 7, SEQ ID NO: 33 to SEQ ID NO: 42, and SEQ ID NO: 45 to SEQ ID NO:
49.
26. The recombinant botulinum toxin according to claim 24, wherein, The variants of the type A botulinum toxin light chain include: The first and second domains of the A1 type botulinum toxin light chain; or variants thereof, and the third and fourth domains of the A4 type botulinum toxin light chain; or variants thereof; or The first and second domains of the A1 type botulinum toxin light chain; or variants thereof, and the third and fourth domains of the A4 type botulinum toxin light chain; or variants thereof, wherein leucine at position 260 is replaced by phenylalanine and isoleucine at position 264 is replaced by arginine.
27. The recombinant botulinum toxin according to claim 24, wherein, When administered to individuals, the recombinant botulinum toxin exhibits greater values in at least one of safety and duration of action compared to wild-type A1 botulinum toxin.
28. A recombinant polypeptide comprising: Translocation domains of type A1 botulinum toxin The translocation domain includes an amino acid mutation at at least one position, wherein the position is a conserved common amino acid in type A2 botulinum toxin and type A6 botulinum toxin, and a different amino acid at the corresponding position in type A1 botulinum toxin.
29. The recombinant polypeptide according to claim 28, wherein, The amino acid mutation position of the translocation domain includes at least one selected from the group consisting of L681, D696, I713, K730, E734, K779, N789, G804, E809, L815, K816, and A818.
30. The recombinant polypeptide according to claim 28, wherein, The translocation domain includes at least one amino acid mutation selected from the group consisting of L681I, D696N, I713T, K730E, E734K, K779S, N789D, G804A, E809K, L815V, K816R, and A818V.
